<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Paediatr Anaesth</journal-id><journal-id journal-id-type="iso-abbrev">Paediatr Anaesth</journal-id><journal-id journal-id-type="publisher-id">pan</journal-id><journal-title-group><journal-title>Paediatric Anaesthesia</journal-title></journal-title-group><issn pub-type="ppub">1155-5645</issn><issn pub-type="epub">1460-9592</issn><publisher><publisher-name>John Wiley &#x00026; Sons Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23570544</article-id><article-id pub-id-type="pmc">4272569</article-id><article-id pub-id-type="doi">10.1111/pan.12163</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Opioid-sparing effects of perioperative paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs) in children</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wong</surname><given-names>Ivan</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>St John-Green</surname><given-names>Celia</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Walker</surname><given-names>Suellen M</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au3">3</xref></contrib><aff id="au1"><label>1</label><institution>Department of Anaesthesia, Great Ormond St Hospital for Children NHS Foundation Trust</institution><addr-line>London, UK</addr-line></aff><aff id="au2"><label>2</label><institution>School of Clinical Medicine, University of Cambridge, Addenbrooke's Hospital</institution><addr-line>Cambridge, UK</addr-line></aff><aff id="au3"><label>3</label><institution>Portex Unit: Pain Research, UCL Institute of Child Health</institution><addr-line>London, UK</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><bold>Correspondence</bold>, Suellen M. Walker, Portex Unit: Pain Research, UCL Institute of Child Health and Great Ormond St Hospital for Children NHS Foundation Trust, 30 Guilford St, London WC1N 1EH, UK, Email: <email>suellen.walker@ucl.ac.uk</email></corresp><fn><p>Section Editor: Per-Arne Lonnqvist</p></fn></author-notes><pub-date pub-type="ppub"><month>6</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>09</day><month>4</month><year>2013</year></pub-date><volume>23</volume><issue>6</issue><fpage>475</fpage><lpage>495</lpage><history><date date-type="accepted"><day>04</day><month>3</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2013 The Authors. <italic>Pediatric Anesthesia</italic> published by John Wiley &#x00026; Sons Ltd</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background and Objectives</title><p>Perioperative pain in children can be effectively managed with systemic opioids, but addition of paracetamol or nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce opioid requirements and potentially improve analgesia and/or reduce adverse effects.</p></sec><sec><title>Methods</title><p>A systematic literature search was conducted to identify trials evaluating postoperative opioid requirements in children and comparing NSAID and/or paracetamol with placebo. Studies were stratified according to design: continuous availability of intravenous opioid (PCA/NCA) vs intermittent &#x02018;as needed&#x02019; bolus; and single vs multiple dose paracetamol/NSAIDs. Primary outcome data were extracted, and the percentage decrease in mean opioid consumption was calculated for statistically significant reductions compared with placebo. Secondary outcomes included differences in pain intensity, adverse effects (sedation, respiratory depression, postoperative nausea and vomiting, pruritus, urinary retention, bleeding), and patient/parent satisfaction.</p></sec><sec><title>Results</title><p>Thirty-one randomized controlled studies, with 48 active treatment arms compared with placebo, were included. Significant opioid sparing was reported in 38 of 48 active treatment arms, across 21 of the 31 studies. Benefit was most consistently reported when multiple doses of study drug were administered, and 24&#x000a0;h PCA or NCA opioid requirements were assessed. The proportion of positive studies was less with paracetamol, but was influenced by dose and route of administration. Despite availability of opioid for titration, a reduction in pain intensity by NSAIDs and/or paracetamol was reported in 16 of 29 studies. Evidence for clinically significant reductions in opioid-related adverse effects was less robust.</p></sec><sec><title>Conclusion</title><p>This systematic review supports addition of NSAIDs and/or paracetamol to systemic opioid for perioperative pain management in children.</p></sec></abstract><kwd-group><kwd>pain</kwd><kwd>postoperative</kwd><kwd>child</kwd><kwd>analgesics</kwd><kwd>opioid</kwd><kwd>analgesics</kwd><kwd>non-narcotic</kwd><kwd>anti-inflammatory agents</kwd><kwd>nonsteroidal</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Systemic opioids are utilized for management of perioperative pain in children of all ages <xref rid="b1" ref-type="bibr">1</xref>,<xref rid="b2" ref-type="bibr">2</xref>. As there are significant developmental changes in both the pharmacokinetic and pharmacodynamic profile of opioids, doses need to be adjusted according to age and weight and titrated against individual response to optimize analgesia and minimize adverse effects <xref rid="b3" ref-type="bibr">3</xref>,<xref rid="b4" ref-type="bibr">4</xref>. This can be achieved by a range of systemic opioid delivery methods, including continuous background infusion, scheduled intermittent boluses <xref rid="b5" ref-type="bibr">5</xref>, nurse-controlled analgesia (NCA) <xref rid="b2" ref-type="bibr">2</xref>, or patient-controlled analgesia (PCA) <xref rid="b1" ref-type="bibr">1</xref>.</p><p>Multi-modal analgesia is recommended for the management of pediatric perioperative pain <xref rid="b3" ref-type="bibr">3</xref>,<xref rid="b6" ref-type="bibr">6</xref>,<xref rid="b7" ref-type="bibr">7</xref> and has the potential to improve analgesic efficacy by simultaneously targeting different analgesic mechanisms and/or reducing the dose requirements of single agents, thereby minimizing dose-dependent adverse effects. Addition of nonsteroidal anti-inflammatory drugs (NSAIDs) and/or paracetamol (acetaminophen) to postoperative opioid regimes is well supported by analyses of adult data <xref rid="b8" ref-type="bibr">8</xref>&#x02013;<xref rid="b11" ref-type="bibr">11</xref>. The quantity and quality of evidence related to pediatric perioperative pain management continue to increase <xref rid="b3" ref-type="bibr">3</xref>,<xref rid="b12" ref-type="bibr">12</xref>, and a recent meta-analysis reported a decrease in opioid dose requirements by perioperative NSAID administration in children <xref rid="b13" ref-type="bibr">13</xref>.</p><p>Variations in design methodology and assessment tools can influence the sensitivity of pediatric analgesic clinical trials <xref rid="b14" ref-type="bibr">14</xref>. This qualitative systematic review aims to stratify evidence according to study design and sensitivity and use within study comparisons to assess the degree to which addition of NSAIDs and/or paracetamol alters postoperative systemic opioid requirements in children. In addition, changes in secondary outcomes (pain scores, drug-related adverse effects, and patient or parental satisfaction) will be summarized.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Search strategy</title><p>Relevant studies were identified by searching electronic databases (PubMed, Embase, CINAHL, Cochrane Library, NHS Evidence) for randomized controlled trials (RCTs) evaluating combinations of systemic paracetamol and/or NSAIDs with systemic opioids for postoperative pain management in children. Key words were used to identify the &#x02018;population&#x02019; (<italic>Children, Pediatric, Pediatric, Neonate, Child, Newborn</italic>), &#x02018;intervention&#x02019; (<italic>paracetamol OR acetaminophen OR NSAIDs OR individual drug names</italic> AND <italic>opioid OR individual opioid names),</italic> and &#x02018;outcomes&#x02019; (<italic>opioid sparing, morbidity, pain score, sedation, respiratory depression, PONV, pruritus, urinary retention, and patient/parent satisfaction)</italic>. Titles and abstracts up to January 2012 were included in the search. Additional relevant titles were identified by manual search of original articles, reviews, and related correspondence. Data were identified, extracted, and presented in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (<ext-link ext-link-type="uri" xlink:href="www.prisma-statement.org">www.prisma-statement.org</ext-link>).</p></sec><sec><title>Selection criteria</title><p>The full reports of RCTs were retrieved and evaluated. Two authors (I.W. and C.St.JG.) independently assessed whether studies met the inclusion criteria, and all three authors discussed and resolved any discrepancies. Criteria for inclusion included the following:<list list-type="order"><list-item><p>Study type: double blind, placebo-controlled trials quantifying the effect of paracetamol and/or NSAID vs placebo on systemic opioid requirements</p></list-item><list-item><p>Participants: children (0&#x02013;18&#x000a0;years) undergoing surgery under general anesthesia</p></list-item><list-item><p>Interventions: multiple or single doses of study drug (paracetamol or NSAID) were administered perioperatively (defined as the first dose administered within an hour prior to induction or following wound closure) by any systemic route (oral, rectal, intramuscular, or intravenous).</p></list-item></list></p><p>Studies were excluded if they had no control group, ongoing regional analgesia, or nonstandardized use of other analgesics that could confound the opioid dose requirements.</p></sec><sec><title>Data extraction</title><p>Details of the study protocol were extracted and tabulated, including: age range of patients; number of patients in each treatment arm; type(s) and duration of surgery; dose regimes for study drugs and opioid (dose, frequency, timing, route and method of delivery); method of pain assessment; criteria for opioid administration; adverse effects; and duration of follow-up. Each included study was graded for quality and scored using the Jadad criteria <xref rid="b15" ref-type="bibr">15</xref>. In addition, the retrieved reports were grouped according to the following aspects of study design:<list list-type="order"><list-item><p>Continuous availability of intravenous opioid titrated according to individual response by PCA, NCA, or variable rate continuous infusion</p></list-item><list-item><p>Intermittent as needed opioid bolus administration</p></list-item><list-item><p>Use of regular repeated doses of paracetamol/NSAIDs for at least 24&#x000a0;h</p></list-item><list-item><p>Use of single dose or less than 6&#x000a0;h paracetamol/NSAIDs.</p></list-item></list></p><p>Secondary outcome data were extracted and included measures of (i) potential opioid-related adverse effects (sedation, respiratory depression, postoperative, nausea and vomiting, pruritus, and urinary retention); (ii) NSAID (increased bleeding, renal dysfunction) and paracetamol (overdose/toxicity) adverse effects; (iii) pain scores; and (iv) patient and/or parent satisfaction.</p></sec><sec><title>Analysis</title><p>The primary outcome was opioid dose requirement in the postoperative period. Studies are reported as &#x02018;positive&#x02019; if a statistically significant reduction in opioid requirements was documented in pair-wise comparisons between the treatment (i.e., paracetamol and/or NSAID) and placebo arm, as previously used in an analysis of similar adult trials <xref rid="b16" ref-type="bibr">16</xref>. The difference between the means of the treatment arms was expressed as a percentage of the corresponding value in the placebo group ([placebo&#x02014;treatment/placebo] &#x000d7;100). Treatment groups in which opioid consumption was not statistically significantly different from the placebo group were designated as &#x02018;negative&#x02019; and assigned an opioid-sparing effect of zero. Due to variability in methodology and reporting, within study comparisons of secondary outcomes in treatment (NSAID or paracetamol) vs placebo groups are reported as being increased, decreased, or not different.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Description and stratification of retrieved studies</title><p>The systematic literature search yielded 104 relevant titles of which 31 met the inclusion criteria (Figure<xref ref-type="fig" rid="f1">1</xref>). All included studies were placebo-controlled blinded trials with quality scores of 3&#x02013;5 on the Jadad scale <xref rid="b15" ref-type="bibr">15</xref>. Recruited children ranged in age from 1.5&#x000a0;months to 17&#x000a0;years old, and all received systemically administered opioids for perioperative analgesia. Several studies included multiple active treatment arms, but only those allowing comparison of opioid consumption in an active and placebo group were included. In total, 988 children were allocated to placebo control arms, and 1636 children received study drugs (paracetamol and/or NSAIDs). Numbers within treatment groups ranged from 13 to 84 subjects. Based on design methodology, studies were stratified according to the availability of opioid (continuous titration vs intermittent bolus) and the duration of study drug administration (either repeat dose for &#x02265;24&#x000a0;h, or single dose &#x02264;6&#x000a0;h) into four groups (Group A&#x02013;D; Figure<xref ref-type="fig" rid="f1">1</xref>).</p><fig id="f1" position="float"><label>Figure 1</label><caption><p>Flow chart of literature search with summary of excluded and included studies and grouping according to study design.</p></caption><graphic xlink:href="pan0023-0475-f1"/></fig><p>In 10 of 31 studies, intravenous opioid was continuously available for titration (Group A and B; Table<xref ref-type="table" rid="tbl1">1</xref>). <xref rid="b17" ref-type="bibr">Morphine 17</xref>&#x02013;<xref rid="b24" ref-type="bibr">24</xref> or fentanyl <xref rid="b25" ref-type="bibr">25</xref>,<xref rid="b26" ref-type="bibr">26</xref> was administered via nurse-controlled (NCA; <italic>n</italic>&#x000a0;=&#x000a0;2) or patient-controlled (PCA; <italic>n</italic>&#x000a0;=&#x000a0;8) bolus administration. Lockout periods ranged from 10 to 30&#x000a0;min for NCA and 3 to 10&#x000a0;min for PCA, and a background infusion was included in six studies (four PCA and both NCA studies). In the 21 studies in Group C <xref rid="b27" ref-type="bibr">27</xref>&#x02013;<xref rid="b30" ref-type="bibr">30</xref> and Group D <xref rid="b31" ref-type="bibr">31</xref>&#x02013;<xref rid="b46" ref-type="bibr">46</xref> (Table<xref ref-type="table" rid="tbl2">2</xref>), opioid was available on an &#x02018;as needed&#x02019; or &#x02018;PRN&#x02019; basis, with nurse administration triggered by a predetermined pain score using either a formal assessment tool (16 studies) or global nursing assessment and patient request (five studies)(Table<xref ref-type="table" rid="tbl3">3</xref>).</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>Study characteristics group A and B: interventions, analgesic administration, and opioid-sparing effects</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Author (reference no.)</th><th align="left" rowspan="1" colspan="1">Surgery and duration (mean&#x000a0;&#x000b1;&#x000a0;<sc>sd</sc> of control group unless stated)</th><th align="left" rowspan="1" colspan="1">Intervention drug, route, and age (mean&#x000a0;&#x000b1;&#x000a0;<sc>sd</sc> unless stated)</th><th align="left" rowspan="1" colspan="1">Timing, frequency, and dose of study drug administration</th><th align="left" rowspan="1" colspan="1">Control and age (mean&#x000a0;&#x000b1;&#x000a0;<sc>sd</sc> unless stated)</th><th align="left" rowspan="1" colspan="1">Opioid</th><th align="left" rowspan="1" colspan="1">Timing, frequency, and dose of opioid</th><th align="left" rowspan="1" colspan="1">Reported opioid dose-sparing effect (% reduction)</th></tr></thead><tbody><tr><td align="left" colspan="8" rowspan="1">GROUP A: Titration of systemic opioid (PCA or NCA) and study drug for &#x02265;24&#x000a0;h</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hong <italic>et al</italic>. <xref rid="b26" ref-type="bibr">26</xref></td><td align="left" rowspan="1" colspan="1">Ureteroneocystostomy<break/>Range: 65&#x02013;135&#x000a0;mins</td><td align="left" rowspan="1" colspan="1">Paracetamol IV (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>31)<break/>Range: 6&#x02013;24&#x000a0;months</td><td align="left" rowspan="1" colspan="1">LOADING: 15&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> at end of surgery<break/>BOLUS (in NCA pump): 1.5&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> with 30&#x000a0;min lockout<break/>INFUSION: 1.5&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup>&#x000b7;h<sup>&#x02212;1</sup> for 72&#x000a0;h<break/>6&#x000a0;h maximum: 15&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> paracetamol</td><td align="left" rowspan="1" colspan="1">Saline (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>32)<break/>Range:6&#x02013;22&#x000a0;months</td><td align="left" rowspan="1" colspan="1">Fentanyl<break/>IV-NCA or parent controlled analgesia with background</td><td align="left" rowspan="1" colspan="1">LOADING DOSE: 0.5&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup> at end of surgery<break/>BACKGROUND: 0.25&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup>&#x000b7;h<sup>&#x02212;1</sup> for 72&#x000a0;h<break/>BOLUS: 0.25&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup> with 30&#x000a0;min lockout<break/>TRIGGER: CHEOPS &#x0003e;4 <xref rid="b4" ref-type="bibr">4</xref>&#x02013;<xref rid="b13" ref-type="bibr">13</xref></td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf1-1">*</xref> (54%)<break/>Paracetamol &#x02013; 8.3&#x000a0;&#x000b1;&#x000a0;3.7<break/>Control &#x02013; 18.1&#x000a0;&#x000b1;&#x000a0;4.6<break/>mcg&#x000b7;kg<sup>&#x02212;1</sup>&#x000b7;day<sup>&#x02212;1</sup>, total dose in first 24&#x000a0;h post-op, mean&#x000a0;&#x000b1;&#x000a0;<sc>sd</sc><break/>POSITIVE<xref ref-type="table-fn" rid="tf1-1">*</xref> (57%)<break/>Paracetamol &#x02013; 20<break/>Control &#x02013; 43<break/>mcg&#x000b7;kg<sup>&#x02212;1</sup>, cumulative fentanyl dose first 3&#x000a0;days, mean</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Rugyte <italic>et al</italic>. <xref rid="b18" ref-type="bibr">18</xref></td><td align="left" rowspan="1" colspan="1">Thoracic pectus correction<break/>Range: 90&#x02013;225&#x000a0;mins</td><td align="left" rowspan="1" colspan="1">Ketoprofen IV (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>14)<break/>Range: 13&#x02013;15&#x000a0;years</td><td align="left" rowspan="1" colspan="1">LOADING: 1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> at end of surgery<break/>MAINTENANCE: 1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> at 8&#x000a0;h and 16&#x000a0;h</td><td align="left" rowspan="1" colspan="1">Saline (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>17)<break/>Range: 10&#x02013;15&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Morphine IV-PCA with background</td><td align="left" rowspan="1" colspan="1">LOADING DOSE: 40&#x000a0;mc&#x000b7;kg<sup>&#x02212;1</sup><break/>BOLUS: 20&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup> with 5&#x000a0;min lockout<break/>BACKGROUND: 5&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup>&#x000b7;h<sup>&#x02212;1</sup><break/>TRIGGER: patient</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf1-1">*</xref> (27%)<break/>Ketoprofen &#x02013; 490&#x000a0;&#x000b1;&#x000a0;240<break/>Control &#x02013; 670&#x000a0;&#x000b1;&#x000a0;200<break/>mcg&#x000b7;kg<sup>&#x02212;1</sup> total dose in first 24&#x000a0;h post-op, mean&#x000a0;&#x000b1;&#x000a0;<sc>sd</sc></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Van der Marel <italic>et al</italic>. <xref rid="b17" ref-type="bibr">17</xref></td><td align="left" rowspan="1" colspan="1">Major abdominal or thoracic (noncardiac) surgery<break/>Range: 60&#x02013;365&#x000a0;mins</td><td align="left" rowspan="1" colspan="1">Paracetamol PR (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>29)<break/>Range: 0&#x02013;9&#x000a0;months</td><td align="left" rowspan="1" colspan="1">LOADING: 30&#x02013;40&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> at induction MAINTENANCE: 20&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup>6&#x02013;8&#x000a0;hrly for 48&#x000a0;h</td><td align="left" rowspan="1" colspan="1">Placebo (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>25)<break/>Range: 0&#x02013;10&#x000a0;months</td><td align="left" rowspan="1" colspan="1">Morphine<break/>IV-NCA with background</td><td align="left" rowspan="1" colspan="1">LOADING DOSE: 100&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup> at end of surgery<break/>BACKGROUND: 5&#x02013;30&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup>&#x000b7;h<sup>&#x02212;1</sup> (depending on gestational age and bolus requirement)<break/>BOLUS: 5&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup> with 10&#x000a0;min lockout<break/>TRIGGER: VAS &#x02265;4 (0&#x02013;10)</td><td align="left" rowspan="1" colspan="1">NEGATIVE (+10)<break/>Paracetamol &#x02212;7.91 (6.59&#x02013;14.02)<break/>Control &#x02013; 7.19 (5.45&#x02013;12.06)<break/>mcg&#x000b7;kg<sup>&#x02212;1</sup>&#x000b7;h<sup>&#x02212;1</sup>, total dose in first 48&#x000a0;h post-op, median (25&#x02013;75th percentile)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Munro <italic>et al</italic>. <xref rid="b19" ref-type="bibr">19</xref></td><td align="left" rowspan="1" colspan="1">Posterior spinal fusion<break/>331&#x000a0;&#x000b1;&#x000a0;62&#x000a0;mins</td><td align="left" rowspan="1" colspan="1">Ketorolac IV (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>20)<break/>13.9&#x000a0;&#x000b1;&#x000a0;1.3&#x000a0;years</td><td align="left" rowspan="1" colspan="1">LOADING: 0.5&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> at end of surgery<break/>MAINTENANCE: 0.5&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> every 6&#x000a0;h for 36&#x000a0;h</td><td align="left" rowspan="1" colspan="1">Saline (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>15)<break/>14.1&#x000a0;&#x000b1;&#x000a0;1.2&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Morphine<break/>IV-PCA with background</td><td align="left" rowspan="1" colspan="1">LOADING DOSE: 50&#x02013;100&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup><break/>BOLUS: 20&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup> (lockout not stated)<break/>BACKGROUND: 10&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup>&#x000b7;h<sup>&#x02212;1</sup><break/>TRIGGER: patient</td><td align="left" rowspan="1" colspan="1">EQUIVOCAL<break/>POSITIVE<xref ref-type="table-fn" rid="tf1-1">*</xref> (33%)<break/>Ketorolac &#x02013; 0.06&#x000a0;&#x000b1;&#x000a0;0.3<break/>Control &#x02013; 0.09&#x000a0;&#x000b1;&#x000a0;0.05<break/>mcg&#x000b7;kg<sup>&#x02212;1</sup>&#x000b7;day<sup>&#x02212;1</sup> during PACU, mean&#x000a0;&#x000b1;&#x000a0;<sc>sd</sc><break/>POSITIVE<xref ref-type="table-fn" rid="tf1-1">*</xref> (30%)<break/>Ketorolac &#x02013; 0.7&#x000a0;&#x000b1;&#x000a0;0.4<break/>Control &#x02013; 1&#x000a0;&#x000b1;&#x000a0;0.5<break/>mcg&#x000b7;kg<sup>&#x02212;1</sup>&#x000b7;day<sup>&#x02212;1</sup> post-op day 2, mean&#x000a0;&#x000b1;&#x000a0;<sc>sd</sc><break/>NEGATIVE (11% n.s.)<break/>Ketorolac &#x02013; 0.8&#x000a0;&#x000b1;&#x000a0;0.3<break/>Control &#x02013; 0.9&#x000a0;&#x000b1;&#x000a0;0.4<break/>mcg&#x000b7;kg<sup>&#x02212;1</sup>&#x000b7;day<sup>&#x02212;1</sup> on post-op day 1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Morton <italic>et al</italic>. <xref rid="b20" ref-type="bibr">20</xref></td><td align="left" rowspan="1" colspan="1">Open Appendicectomy<break/>Duration not reported</td><td align="left" rowspan="1" colspan="1">Paracetamol PR (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>20)<break/>Range: 5&#x02013;12&#x000a0;years<break/>Diclofenac PR (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>20)<break/>Range: 6&#x02013;13&#x000a0;years<break/>Combination (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>20)<break/>Range: 7&#x02013;13&#x000a0;years</td><td align="left" rowspan="1" colspan="1">LOADING: paracetamol 20&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> AND/OR diclofenac 1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup><break/>MAINTENANCE: paracetamol 15&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> 6&#x000a0;hrly AND/OR diclofenac 1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> 8&#x000a0;hrly for 24&#x000a0;h post-op</td><td align="left" rowspan="1" colspan="1">Control: no treatment (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>20)<break/>Range: 5&#x02013;13&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Morphine<break/>IV-PCA with background</td><td align="left" rowspan="1" colspan="1">BOLUS: 20&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup> with 5&#x000a0;min lockout<break/>BACKGROUND: 4&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup>&#x000b7;h<sup>&#x02212;1</sup> infusion for first 12&#x000a0;h post-op<break/>TRIGGER: patient</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf1-1">*</xref> (Diclofenac 43%, Combination 36%)<break/>Diclofenac &#x02013; 435 (101&#x02013;1054)<break/>Combination &#x02013; 484 (126&#x02013;1214)<break/>Control &#x02013; 759 (368&#x02013;1914)<break/>NEGATIVE (Paracetamol 17% n.s)<break/>Paracetamol &#x02013; 627 (124&#x02013;1339)<break/>mcg&#x000b7;kg<sup>&#x02212;1</sup>, total dose in first 24&#x000a0;h post-op, median (range)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Sutters <italic>et al</italic>. <xref rid="b22" ref-type="bibr">22</xref></td><td align="left" rowspan="1" colspan="1">Orthopedic surgery<break/>178.2&#x000a0;&#x000b1;&#x000a0;105.8&#x000a0;mins</td><td align="left" rowspan="1" colspan="1">Ketorolac IV (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>36)<break/>12.6&#x000a0;&#x000b1;&#x000a0;3.5&#x000a0;years</td><td align="left" rowspan="1" colspan="1">LOADING: 1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> in recovery<break/>MAINTENANCE: 0.5&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> 6&#x000a0;hrly for 48&#x000a0;h post-op</td><td align="left" rowspan="1" colspan="1">Saline (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>32)<break/>12.6&#x000a0;&#x000b1;&#x000a0;4.2&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Morphine<break/>IV-PCA</td><td align="left" rowspan="1" colspan="1">LOADING DOSE: NCA boluses in recovery<break/>BOLUS: 16&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup> with 10&#x000a0;min lockout<break/>TRIGGER: patient</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf1-1">*</xref> (47%)<break/>Ketorolac &#x02013; 3.37&#x000a0;&#x000b1;&#x000a0;2.66<break/>Control &#x02013; 6.38&#x000a0;&#x000b1;&#x000a0;4.36&#x000a0;<break/>mg, total dose in first 24&#x000a0;h post-op, mean&#x000a0;&#x000b1;&#x000a0;<sc>sd</sc></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Sims <italic>et al</italic>. <xref rid="b21" ref-type="bibr">21</xref></td><td align="left" rowspan="1" colspan="1">Emergency open appendicectomy<break/>39&#x000a0;&#x000b1;&#x000a0;12&#x000a0;mins</td><td align="left" rowspan="1" colspan="1">Indomethacin PR (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>13)<break/>10.1&#x000a0;&#x000b1;&#x000a0;1.8&#x000a0;years</td><td align="left" rowspan="1" colspan="1">LOADING: 2&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> at end of surgery<break/>MAINTENANCE: 2&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> at 12&#x000a0;h and 24&#x000a0;h post-op</td><td align="left" rowspan="1" colspan="1">Placebo (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>15)<break/>10.7&#x000a0;&#x000b1;&#x000a0;2.1&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Morphine<break/>IV-PCA</td><td align="left" rowspan="1" colspan="1">BOLUS: 20&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup> with 3&#x000a0;min lockout<break/>TRIGGER: patient</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf1-1">*</xref> (44%)<break/>Indomethacin &#x02013; 0.51&#x000a0;&#x000b1;&#x000a0;0.34<break/>Placebo &#x02013; 0.91&#x000a0;&#x000b1;&#x000a0;0.46&#x000a0;<break/>mg, total dose first 36&#x000a0;h post-op, mean&#x000a0;&#x000b1;&#x000a0;<sc>sd</sc></td></tr><tr><td align="left" colspan="8" rowspan="1">GROUP B: Titration of systemic opioid and single dose (&#x02264;6&#x000a0;h) study drug</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Antila <italic>et al</italic>. <xref rid="b25" ref-type="bibr">25</xref></td><td align="left" rowspan="1" colspan="1">Tonsillectomy<break/>17&#x000a0;&#x000b1;&#x000a0;7&#x000a0;mins</td><td align="left" rowspan="1" colspan="1">Ketoprofen IV (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>15)<break/>12.5&#x000a0;&#x000b1;&#x000a0;2.3&#x000a0;years</td><td align="left" rowspan="1" colspan="1">2&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> at induction<break/>PLUS 2&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> infusion over 6&#x000a0;h post-op</td><td align="left" rowspan="1" colspan="1">Saline (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>15)<break/>12.5&#x000a0;&#x000b1;&#x000a0;1.9&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Fentanyl<break/>IV-PCA</td><td align="left" rowspan="1" colspan="1">BOLUS: 0.5&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup> with 5&#x000a0;min lockout<break/>TRIGGER: patient</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf1-1">*</xref> (14%)<break/>Ketoprofen &#x02013; 11.9&#x000a0;&#x000b1;&#x000a0;8.8<break/>Placebo &#x02013; 13.9&#x000a0;&#x000b1;&#x000a0;7.9<break/>mcg&#x000b7;kg<sup>&#x02212;1</sup> total dose in first 24&#x000a0;h post-op, mean&#x000a0;&#x000b1;&#x000a0;<sc>sd</sc></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Oztekin <italic>et al</italic>. <xref rid="b24" ref-type="bibr">24</xref></td><td align="left" rowspan="1" colspan="1">Tonsillectomy&#x000a0;&#x000b1;&#x000a0;adenoidectomy<break/>57.8&#x000a0;&#x000b1;&#x000a0;3.23&#x000a0;mins</td><td align="left" rowspan="1" colspan="1">Diclofenac PR (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>20)<break/>8.40&#x000a0;&#x000b1;&#x000a0;0.53&#x000a0;years</td><td align="left" rowspan="1" colspan="1">1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> prior to incision</td><td align="left" rowspan="1" colspan="1">Control: no treatment (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>20)<break/>8.90&#x000a0;&#x000b1;&#x000a0;0.45&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Morphine<break/>IV-PCA with background</td><td align="left" rowspan="1" colspan="1">LOADING DOSE: 50 mcg&#x000b7;kg<sup>&#x02212;1</sup> at end of surgery<break/>BOLUS: 20&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup> bolus with 5&#x000a0;min lockout<break/>BACKGROUND: 4&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup>&#x000b7;h<sup>&#x02212;1</sup> infusion<break/>TRIGGER: patient</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf1-1">*</xref> (24%)<break/>Diclofenac &#x02013; 130&#x000a0;&#x000b1;&#x000a0;11.3<break/>Control &#x02013; 170&#x000a0;&#x000b1;&#x000a0;9.22<break/>microgram&#x000b7;kg<sup>&#x02212;1</sup>, in PACU, mean&#x000a0;&#x000b1;&#x000a0;<sc>sd</sc></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Vetter <italic>et al</italic>. <xref rid="b23" ref-type="bibr">23</xref></td><td align="left" rowspan="1" colspan="1">Orthopedic surgery<break/>(osteotomy, arthrodesis, ORIF) 113&#x000a0;&#x000b1;&#x000a0;42&#x000a0;mins</td><td align="left" rowspan="1" colspan="1">Ketorolac IV (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>25)<break/>13&#x000a0;&#x000b1;&#x000a0;2.0&#x000a0;years</td><td align="left" rowspan="1" colspan="1">0.8&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> at end of surgery</td><td align="left" rowspan="1" colspan="1">Control: no treatment (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>25)<break/>13&#x000a0;&#x000b1;&#x000a0;2.0&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Morphine<break/>IV-PCA</td><td align="left" rowspan="1" colspan="1">LOADING DOSE: 0.05 to 0.3&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> in recovery<break/>BOLUS: 15&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup> with 10&#x000a0;min lockout<break/>TRIGGER: patient</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf1-1">*</xref> (35%)<break/>Ketorolac &#x02013; 0.017&#x000a0;&#x000b1;&#x000a0;0.008<break/>Control &#x02013; 0.026&#x000a0;&#x000b1;&#x000a0;0.011&#x000a0;<break/>mg&#x000b7;kg<sup>&#x02212;1</sup>&#x000b7;h<sup>&#x02212;1</sup>, in first 12&#x000a0;h post-op, mean&#x000a0;&#x000b1;&#x000a0;<sc>sd</sc></td></tr></tbody></table><table-wrap-foot><fn id="tf1-1"><label>*</label><p>Positive, statistically significant opioid dose-sparing effect reported by authors; Negative, no statistically significant difference in opioid requirements.</p></fn><fn><p>PR, per rectum; IV, intravenous; IM, intramuscular.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p>Study characteristics group C and D: interventions, analgesic administration and opioid-sparing effects</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Author (reference no.)</th><th align="left" rowspan="1" colspan="1">Surgery and duration (mean &#x000b1; <sc>sd</sc> of control group unless stated)</th><th align="left" rowspan="1" colspan="1">Intervention drug, route and age (mean&#x000a0;&#x000b1;&#x000a0;<sc>sd</sc> unless stated)</th><th align="left" rowspan="1" colspan="1">Timing, frequency and dose of study drug administration</th><th align="left" rowspan="1" colspan="1">Control and age (mean &#x000b1; <sc>sd</sc> unless stated)</th><th align="left" rowspan="1" colspan="1">Opioid</th><th align="left" rowspan="1" colspan="1">Frequency and dose of opioid trigger (pain score) for administration</th><th align="left" rowspan="1" colspan="1">Opioid dose-sparing effect (% reduction)</th></tr></thead><tbody><tr><td align="left" colspan="8" rowspan="1">GROUP C: Intermittent opioid bolus and study drug for &#x02265;24&#x000a0;h</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<xref rid="b27" ref-type="bibr">Mireskandari 27</xref></td><td align="left" rowspan="1" colspan="1">Cleft palate repair<break/>81.7&#x000a0;&#x000b1;&#x000a0;30.1 mins</td><td align="left" rowspan="1" colspan="1">Paracetamol PR (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>30) 2.1&#x000a0;&#x000b1;&#x000a0;0.8&#x000a0;years<break/>Diclofenac PR (n&#x000a0;=&#x000a0;30)<break/>2.2&#x000a0;&#x000b1;&#x000a0;1.1&#x000a0;years<break/>Combination (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>30)<break/>2.0&#x000a0;&#x000b1;&#x000a0;0.5&#x000a0;years</td><td align="left" rowspan="1" colspan="1">30&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> paracetamol, 1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> diclofenac or combination 8 hrly for 48&#x000a0;h</td><td align="left" rowspan="1" colspan="1">Placebo PR (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>30)<break/>2.3&#x000a0;&#x000b1;&#x000a0;1&#x000a0;year</td><td align="left" rowspan="1" colspan="1">Pethidine IM</td><td align="left" rowspan="1" colspan="1">BOLUS: 1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> IM<break/>TRIGGER: CHEOPS &#x0003e;7</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf2-1">*</xref> (9 &#x02013; 47%)<break/>Paracetamol &#x02013; 88.3&#x000a0;&#x000b1;&#x000a0;8.3 (9%)<break/>Diclofenac &#x02013; 70.7&#x000a0;&#x000b1;&#x000a0;10 (27%)<break/>Combined &#x02013; 51&#x000a0;&#x000b1;&#x000a0;9.5 (47%)<break/>Control &#x02013; 97.1&#x000a0;&#x000b1;&#x000a0;13.9<break/>Total pethidine dose in first 48&#x000a0;h post-op<break/>Paracetamol &#x02013; 6.2&#x000a0;&#x000b1;&#x000a0;0.6 (11%)<break/>Diclofenac &#x02013; 4.9&#x000a0;&#x000b1;&#x000a0;0.7 (28%)<break/>Combined &#x02013; 3.6&#x000a0;&#x000b1;&#x000a0;0.7 (47%)<break/>Control &#x02013; 6.8&#x000a0;&#x000b1;&#x000a0;0.9<break/>No. of doses in first 48&#x000a0;h</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Kokki <italic>et al</italic>. <xref rid="b28" ref-type="bibr">28</xref></td><td align="left" rowspan="1" colspan="1">Tonsillectomy<break/>25&#x000a0;&#x000b1;&#x000a0;12 mins</td><td align="left" rowspan="1" colspan="1">Ketoprofen IV<break/>Pre-op (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>47)<break/>10&#x000a0;&#x000b1;&#x000a0;1 years post-op (n&#x000a0;=&#x000a0;42)<break/>12&#x000a0;&#x000b1;&#x000a0;3&#x000a0;years</td><td align="left" rowspan="1" colspan="1">LOADING: 0.5&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> after induction (n&#x000a0;=&#x000a0;47) OR end of surgery (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>42) MAINTENANCE: 3&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> infusion over 24&#x000a0;h</td><td align="left" rowspan="1" colspan="1">Saline (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>20)<break/>11&#x000a0;&#x000b1;&#x000a0;1&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Oxycodone IV or IM</td><td align="left" rowspan="1" colspan="1">BOLUS: 0.05&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> IV or 0.1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> IM<break/>TRIGGER: VAS &#x0003e;30&#x000a0;mm</td><td align="left" rowspan="1" colspan="1">NEGATIVE<break/>Preop ketoprofen &#x02013; 4.1&#x000a0;&#x000b1;&#x000a0;2.7 (19% n.s.)<break/>post-op ketoprofen &#x02013; 3.7&#x000a0;&#x000b1;&#x000a0;2.4 (27% n.s.)<break/>Control &#x02013; 5.1&#x000a0;&#x000b1;&#x000a0;2.7<break/>No. of doses in first 24&#x000a0;h post-op, mean&#x000a0;&#x000b1;&#x000a0;sd</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Maunuksela <italic>et al</italic>. <xref rid="b29" ref-type="bibr">29</xref></td><td align="left" rowspan="1" colspan="1">Ophthalmic, general or orthopedic surgery<break/>Control group:<break/>50.1&#x000a0;&#x000b1;&#x000a0;39.4&#x000a0;mins</td><td align="left" rowspan="1" colspan="1">Ibuprofen PR (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>64)<break/>7.7&#x000a0;&#x000b1;&#x000a0;2.7&#x000a0;years</td><td align="left" rowspan="1" colspan="1">LOADING: 10&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup><break/>MAINTENANCE: total 40&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> 6&#x02013;8 hrly for 24&#x000a0;h</td><td align="left" rowspan="1" colspan="1">Placebo z(<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>64)<break/>7.4&#x000a0;&#x000b1;&#x000a0;2.7&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Morphine or Oxycodone (different centers)<break/>IV or IM</td><td align="left" rowspan="1" colspan="1">BOLUS: 0.1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> IV in recovery; 0.15&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> IM on ward<break/>TRIGGER: OPS moderate/severe or patient request</td><td align="left" rowspan="1" colspan="1">EQUIVOCAL<break/>POSITIVE<xref ref-type="table-fn" rid="tf2-1">*</xref> (orthop surgery 36%)<break/>Ibuprofen (n&#x000a0;=&#x000a0;12) &#x02013; 0.27&#x000a0;&#x000b1;&#x000a0;0.20<break/>Control (n&#x000a0;=&#x000a0;19) &#x02013; 0.42&#x000a0;&#x000b1;&#x000a0;0.23<break/>NEGATIVE (other surgery 25% n.s.)<break/>Ibuprofen (n&#x000a0;=&#x000a0;52) &#x02013; 0.09&#x000a0;&#x000b1;&#x000a0;0.11<break/>Control (n&#x000a0;=&#x000a0;45) &#x02013; 0.12&#x000a0;&#x000b1;&#x000a0;0.1&#x000a0;<break/>mg&#x000b7;kg<sup>&#x02212;1</sup>, total opioid dose in first 24&#x000a0;h post-op, mean &#x000b1; <sc>sd</sc></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Maunuksela <italic>et al</italic>. <xref rid="b30" ref-type="bibr">30</xref></td><td align="left" rowspan="1" colspan="1">Orthopedic or general surgery<break/>0.85&#x000a0;&#x000b1;&#x000a0;0.61&#x000a0;h</td><td align="left" rowspan="1" colspan="1">Indomethacin IV (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>51)<break/>7.0&#x000a0;&#x000b1;&#x000a0;5.1&#x000a0;years</td><td align="left" rowspan="1" colspan="1">BOLUS: 0.35&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> at end of surgery<break/>MAINTENANCE: 0.07&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup>&#x000b7;h<sup>&#x02212;1</sup> for 24&#x000a0;h</td><td align="left" rowspan="1" colspan="1">Placebo (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>49)<break/>6.1&#x000a0;&#x000b1;&#x000a0;4.3&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Morphine IV or IM</td><td align="left" rowspan="1" colspan="1">BOLUS: 0.1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> IV in recovery; 0.15&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> IM on ward<break/>TRIGGER: Maunuksela score &#x0003e;3 or patient request</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf2-1">*</xref> (28%)<break/>Indomethacin &#x02013; 0.24&#x000a0;&#x000b1;&#x000a0;0.17<break/>Control &#x02013; 0.33&#x000a0;&#x000b1;&#x000a0;0.21&#x000a0;<break/>mg&#x000b7;kg<sup>&#x02212;1</sup>, total morphine dose in first 24&#x000a0;h post-op, mean&#x000a0;&#x000b1;&#x000a0;<sc>sd</sc></td></tr><tr><td align="left" colspan="8" rowspan="1">GROUP D: Intermittent opioid bolus and Single dose study drug</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hong <italic>et al</italic>. <xref rid="b31" ref-type="bibr">31</xref></td><td align="left" rowspan="1" colspan="1">Inguinal hernia repair (day case)<break/>33.0&#x000a0;&#x000b1;&#x000a0;11.7&#x000a0;mins</td><td align="left" rowspan="1" colspan="1">Ketorolac + Paracetamol IV (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>28)<break/>28.4&#x000a0;&#x000b1;&#x000a0;15.5&#x000a0;months</td><td align="left" rowspan="1" colspan="1">1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> ketorolac + 20&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> paracetamol after induction</td><td align="left" rowspan="1" colspan="1">Saline (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>27)<break/>28.0&#x000a0;&#x000b1;&#x000a0;13.3&#x000a0;months</td><td align="left" rowspan="1" colspan="1">Fentany lIV</td><td align="left" rowspan="1" colspan="1">BOLUS: 0.5 mcg&#x000b7;kg<sup>&#x02212;1</sup><break/>TRIGGER: Wong-Baker score &#x0003e;2</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf2-1">*</xref> (61%)<break/>Ketorolac-Paracetamol &#x02013; 0.54&#x000a0;&#x000b1;&#x000a0;0.3<break/>Control &#x02013; 1.37&#x000a0;&#x000b1;&#x000a0;0.2<break/>microgram&#x000b7;kg<sup>&#x02212;1</sup>, in PACU, mean&#x000a0;&#x000b1;&#x000a0;<sc>sd</sc></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Dashti <italic>et al</italic>. <xref rid="b32" ref-type="bibr">32</xref></td><td align="left" rowspan="1" colspan="1">Adenotonsillectomy<break/>Duration not reported</td><td align="left" rowspan="1" colspan="1">Paracetamol PR (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>53)<break/>10.2&#x000a0;&#x000b1;&#x000a0;2.84&#x000a0;years</td><td align="left" rowspan="1" colspan="1">40&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> given after Induction</td><td align="left" rowspan="1" colspan="1">Control: no treatment (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>51)<break/>9.45&#x000a0;&#x000b1;&#x000a0;2.22&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Pethidine (meperidine)<break/>IV</td><td align="left" rowspan="1" colspan="1">BOLUS: 0.5&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup><break/>TRIGGER: VAS&#x0003e;40&#x000a0;mm</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf2-1">*</xref> (62%)<break/>Paracetamol &#x02013; 6.48&#x000a0;&#x000b1;&#x000a0;8.52<break/>Control - 17.09&#x000a0;&#x000b1;&#x000a0;12.12&#x000a0;<break/>mg, total dose in first 24&#x000a0;h post-op, mean&#x000a0;&#x000b1;&#x000a0;<sc>sd</sc></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Korpela <italic>et al</italic>. <xref rid="b33" ref-type="bibr">33</xref></td><td align="left" rowspan="1" colspan="1">Adenoidectomy (day case)<break/>Duration not reported</td><td align="left" rowspan="1" colspan="1">Paracetamol oral (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>30)<break/>Median &#x00026; range:<break/>1.7 (0.8 &#x02013; 5) years<break/>Naproxen oral (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>30)<break/>median &#x00026; range:<break/>1.9 (0.8 &#x02013; 7.8) years</td><td align="left" rowspan="1" colspan="1">Paracetamol 20&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> or Naproxen 10&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> given 0.5&#x000a0;h before induction</td><td align="left" rowspan="1" colspan="1">Placebo (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>30)<break/>median and range: 1.7 (0.8 &#x02013; 6.2) years</td><td align="left" rowspan="1" colspan="1">Fentany lIV</td><td align="left" rowspan="1" colspan="1">BOLUS: 10 mcg&#x000b7;kg<sup>&#x02212;1</sup><break/>TRIGGER: OPS &#x0003e;4</td><td align="left" rowspan="1" colspan="1">EQUIVOCAL<break/>POSITIVE<xref ref-type="table-fn" rid="tf2-1">*</xref> (Naproxen 19%)<break/>Naproxen &#x02013; 17/30 (19%)<break/>Paracetamol &#x02013; 20/30 (5% n.s.)<break/>Control &#x02013; 21/30<break/>Proportion requiring fentanyl in first 2&#x000a0;h post-op<break/><italic>Note: data only from groups given standardized intra-operative analgesia (pethidine 1&#x000a0;</italic>mg&#x000b7;kg<sup>&#x02212;1</sup><italic>)</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Sheeran <italic>et al</italic>. <xref rid="b34" ref-type="bibr">34</xref></td><td align="left" rowspan="1" colspan="1">Adenotonsillectomy (day case)<break/>Duration not reported</td><td align="left" rowspan="1" colspan="1">Rofecoxib oral (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>23)<break/>7.2&#x000a0;&#x000b1;&#x000a0;1.8&#x000a0;years</td><td align="left" rowspan="1" colspan="1">1&#x000a0;mg.kg given 0.5&#x000a0;h before induction</td><td align="left" rowspan="1" colspan="1">Placebo (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>22)<break/>7.6&#x000a0;&#x000b1;&#x000a0;2.2&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Morphine IV</td><td align="left" rowspan="1" colspan="1">BOLUS: 25&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup><break/>TRIGGER: nurse assessment</td><td align="left" rowspan="1" colspan="1">NEGATIVE (0%)<break/>Rofecoxib &#x02013; 39&#x000a0;&#x000b1;&#x000a0;28<break/>Control &#x02013; 39&#x000a0;&#x000b1;&#x000a0;32<break/>microgram&#x000b7;kg<sup>&#x02212;1</sup>, in first 24&#x000a0;h post-op, mean&#x000a0;&#x000b1; <sc>sd</sc></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Viitanen <italic>et al</italic>. <xref rid="b35" ref-type="bibr">35</xref></td><td align="left" rowspan="1" colspan="1">Adenoidectomy (day case)<break/>30&#x000a0;&#x000b1;&#x000a0;9&#x000a0;mins</td><td align="left" rowspan="1" colspan="1">Paracetamol PR (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>40),<break/>1.0&#x02013;6.4&#x000a0;years<break/>Ibuprofen PR (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>40), 1.0&#x02013;6.9&#x000a0;years<break/>Combination (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>40)<break/>1.0&#x02013;6.9&#x000a0;years</td><td align="left" rowspan="1" colspan="1">40&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> paracetamol;<break/>15&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> ibuprofen;<break/>combination given at induction</td><td align="left" rowspan="1" colspan="1">Placebo (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>40)<break/>Range: 1.0&#x02013;6.3&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Pethidine (meperidine) IV</td><td align="left" rowspan="1" colspan="1">BOLUS: 5 or 10&#x000a0;mg<break/>TRIGGER: OPS &#x0003e;3</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf2-1">*</xref> (Paracetamol 19%, Ibuprofen 27%,<break/>Combination 28%)<break/>Paracetamo&#x02013; 0.87&#x000a0;&#x000b1;&#x000a0;0.39 (19%)<break/>Ibuprofen - 0.78&#x000a0;&#x000b1;&#x000a0;0.37 (27%)<break/>Combination &#x02013; 0.77&#x000a0;&#x000b1;&#x000a0;0.45 (28%)<break/>Control &#x02013; 1.07&#x000a0;&#x000b1;&#x000a0;0.38&#x000a0;<break/>mg&#x000b7;kg<sup>&#x02212;1</sup>, total dose in PACU, mean&#x000a0;&#x000b1;&#x000a0;<sc>sd</sc></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Tuomilehto <italic>et al</italic>. <xref rid="b36" ref-type="bibr">36</xref></td><td align="left" rowspan="1" colspan="1">Adenoidectomy<break/>Duration not reported</td><td align="left" rowspan="1" colspan="1">Ketoprofen IV<break/>(<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>40)<break/>Median: 30 (15&#x02013;75) months<break/>Ketoprofen IM<break/>(<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>40)<break/>Median: 42 (12&#x02013;100) months</td><td align="left" rowspan="1" colspan="1">2&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> IV at induction<break/>OR<break/>2&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> IM at induction</td><td align="left" rowspan="1" colspan="1">Saline<break/>(<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>40)<break/>Median: 33 (16&#x02013;85) months</td><td align="left" rowspan="1" colspan="1">Fentanyl IV</td><td align="left" rowspan="1" colspan="1">BOLUS: 0.5&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup><break/>TRIGGER: Maunuksela &#x0003e;3</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf2-1">*</xref> (IV 28% IM 23%)<break/>IV - 25/40<break/>IM - 27/40<break/>Placebo - 35/40<break/>Proportion requiring rescue analgesia in PACU</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Bremerich <italic>et al</italic>. <xref rid="b37" ref-type="bibr">37</xref></td><td align="left" rowspan="1" colspan="1">Cleft palate repair<break/>Control group<break/>109.9&#x000a0;&#x000b1;&#x000a0;29.1&#x000a0;mins</td><td align="left" rowspan="1" colspan="1">Paracetamol PR<break/>mg&#x000b7;kg<sup>&#x02212;1</sup> (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>20)<break/>11.7&#x000a0;&#x000b1;&#x000a0;8.8&#x000a0;months<break/>20&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>20)<break/>&#x000a0;12.1&#x000a0;&#x000b1;&#x000a0;10.4&#x000a0;months<break/>&#x000a0;40&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>20)<break/>&#x000a0;9.5&#x000a0;&#x000b1;&#x000a0;9.0&#x000a0;months</td><td align="left" rowspan="1" colspan="1">10&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>20), 20&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>20), or 40&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>20),<break/>given at induction</td><td align="left" rowspan="1" colspan="1">Placebo (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>20)<break/>12.5&#x000a0;&#x000b1;&#x000a0;11.7&#x000a0;months</td><td align="left" rowspan="1" colspan="1">Piritramide<break/>IV</td><td align="left" rowspan="1" colspan="1">BOLUS: 25&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup><break/>TRIGGER: CHIPPS &#x0003e;4</td><td align="left" rowspan="1" colspan="1">NEGATIVE<break/>Paracetamol 10&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> &#x02013; 3.0&#x000a0;&#x000b1;&#x000a0;1.2 (+10%)<break/>Paracetamol 20&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> &#x02013; 3.2&#x000a0;&#x000b1;&#x000a0;1.3 (+18%)<break/>Paracetamol 40&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> &#x02013; 3.4&#x000a0;&#x000b1;&#x000a0;1.1 (+26%)<break/>Placebo &#x02013; 2.7&#x000a0;&#x000b1;&#x000a0;1.6<break/>Total no. of doses of piritramide in PACU, mean&#x000a0;&#x000b1;&#x000a0;<sc>sd</sc></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Kokki <italic>et al</italic>. <xref rid="b38" ref-type="bibr">38</xref></td><td align="left" rowspan="1" colspan="1">Adenoidectomy<break/>Duration not reported</td><td align="left" rowspan="1" colspan="1">Ketoprofen PR (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>42)<break/>Median 33 (17&#x02013;90) months<break/>Ketoprofen IV (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>42)<break/>Median: 44 (15&#x02013;97) months</td><td align="left" rowspan="1" colspan="1">25&#x000a0;mg PR 30&#x000a0;mins prior to induction<break/>Or<break/>25&#x000a0;mg IV at induction</td><td align="left" rowspan="1" colspan="1">Placebo PR &#x00026; saline IV<break/>(<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>39)<break/>Median:<break/>45 (14&#x02013;73) months</td><td align="left" rowspan="1" colspan="1">Fentanyl IV</td><td align="left" rowspan="1" colspan="1">BOLUS: 0.5&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup> in recovery<break/>TRIGGER: Maunuksela &#x0003e;3</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf2-1">*</xref>(PR 24% IV 22%)<break/>PR &#x02013; 27/42<break/>IV &#x02013; 28/42<break/>Control - 33/39<break/>Proportion requiring rescue analgesia in PACU<break/>POSITIVE<xref ref-type="table-fn" rid="tf2-1">*</xref>(PR 52% IV 63%)<break/>PR &#x02013; 9/42<break/>IV &#x02013; 7/42<break/>Control &#x02013; 17/39<break/>Proportion requiring &#x02265;3 rescue doses in PACU</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Tuomilehto <italic>et al</italic>. <xref rid="b47" ref-type="bibr">47</xref></td><td align="left" rowspan="1" colspan="1">Adenoidectomy<break/>Duration: 17 <xref rid="b8" ref-type="bibr">8</xref>&#x02013;<xref rid="b37" ref-type="bibr">37</xref>&#x000a0;mins</td><td align="left" rowspan="1" colspan="1">Ketoprofen PO (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>40)<break/>Median: 50 (20&#x02013;101) months<break/>Ketoprofen IV<break/>(<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>40)<break/>Median: 32 (16&#x02013;82) months</td><td align="left" rowspan="1" colspan="1">1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> PO 30&#x000a0;mins prior to induction<break/>Or<break/>1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> IV at induction</td><td align="left" rowspan="1" colspan="1">Saline PO &#x00026; IV<break/>(<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>20)<break/>Median: 46 (15&#x02013;101) months</td><td align="left" rowspan="1" colspan="1">Fentanyl<break/>IV</td><td align="left" rowspan="1" colspan="1">BOLUS: 0.5&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup> in recovery<break/>TRIGGER: Maunuksela &#x0003e;3</td><td align="left" rowspan="1" colspan="1">EQUIVOCAL<break/>NEGATIVE<break/>IV &#x02013; 30/40 Oral &#x02013; 28/40 Control &#x02013; 15/20<break/>Proportion requiring rescue analgesia in PACU<break/>POSITIVE<xref ref-type="table-fn" rid="tf2-1">*</xref>Oral &#x02013; 6/40<break/>IV &#x02013; 3/40<break/>Control &#x02013; 6/20<break/>Proportion requiring &#x02265;3 rescue doses in PACU</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Kokki <italic>et al</italic>. <xref rid="b40" ref-type="bibr">40</xref></td><td align="left" rowspan="1" colspan="1">Strabismus surgery<break/>Median (quartiles):<break/>30 <xref rid="b23" ref-type="bibr">23</xref>&#x02013;<xref rid="b45" ref-type="bibr">45</xref>&#x000a0;mins</td><td align="left" rowspan="1" colspan="1">Ketoprofen IV (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>30)<break/>Median (quartiles):<break/>83 (50&#x02013;112) months</td><td align="left" rowspan="1" colspan="1">LOADING: 1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> after induction<break/>MAINTENANCE: 1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> infusion over 2&#x000a0;h</td><td align="left" rowspan="1" colspan="1">Saline (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>29)<break/>Median (quartiles):<break/>64 (46&#x02013;94) months</td><td align="left" rowspan="1" colspan="1">Fentany<break/>lIV</td><td align="left" rowspan="1" colspan="1">BOLUS: 1.0&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup><break/>TRIGGER: Maunuksela &#x0003e;3</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf2-1">*</xref> (28%)<break/>Ketoprofen &#x02013; 21/30<break/>Control &#x02013; 26/29<break/>Proportion requiring fentanyl in first 2&#x000a0;h<break/>POSITIVE<xref ref-type="table-fn" rid="tf2-1">*</xref> (29%)<break/>Ketoprofen &#x02013; 44<break/>Control &#x02013; 62<break/>Total doses fentanyl per group first 2&#x000a0;h post-op</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Korpela <italic>et al</italic>. <xref rid="b39" ref-type="bibr">39</xref></td><td align="left" rowspan="1" colspan="1">Inguinal surgery, adenoidectomy, general surgery (day case)<break/>Duration not reported</td><td align="left" rowspan="1" colspan="1">Paracetamol PR (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>90)<break/>20&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> range:<break/>1.0&#x02013;7.2&#x000a0;years<break/>40&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> range:<break/>1.0&#x02013;7.2&#x000a0;years<break/>60&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> range:<break/>1.1&#x02013;7.8&#x000a0;years</td><td align="left" rowspan="1" colspan="1">20&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>30), 40&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>30), or 60&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>30)<break/>given at induction</td><td align="left" rowspan="1" colspan="1">Placebo (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>30)<break/>1.1&#x02013;7.7&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Morphine<break/>IV</td><td align="left" rowspan="1" colspan="1">BOLUS: 0.1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup><break/>TRIGGER: nurse assessment</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf2-1">*</xref> (20&#x000a0;mg 27%, 40&#x000a0;mg 54%, 60&#x000a0;mg 73%)<break/>Paracetamol 20&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> &#x02013; 0.8<break/>Paracetamol 40&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> &#x02013; 0.5<break/>Paracetamol 60&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> &#x02013; 0.3<break/>Control &#x02013; 1.1<break/>Total no. of doses of morphine per patient in first 2&#x000a0;h post-op, mean</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Kokki <italic>et al</italic>. <xref rid="b41" ref-type="bibr">41</xref></td><td align="left" rowspan="1" colspan="1">Adenoidectomy (day case)<break/>Duration not reported</td><td align="left" rowspan="1" colspan="1">Ketoprofen IV (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>165)<break/>0.3&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> median (10th&#x02013;90th percentile):<break/>40 (18&#x02013;74) months1.0&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup>: 32 (15&#x02013;85) months3.0&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup>: 32 (15&#x02013;72) months</td><td align="left" rowspan="1" colspan="1">0.3&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>55) 1.0&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>55)<break/>3.0&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>55)<break/>given at induction</td><td align="left" rowspan="1" colspan="1">Saline (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>55)<break/>Median (10th&#x02013;90th percentile):<break/>41 (15&#x02013;79) months</td><td align="left" rowspan="1" colspan="1">FentanylI<break/>V</td><td align="left" rowspan="1" colspan="1">BOLUS: 1.0&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup><break/>TRIGGER: Maunuksela &#x0003e;3</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf2-1">*</xref> (0.3&#x000a0;mg 21%, 1.0&#x000a0;mg 24%, 3.0&#x000a0;mg 35%)<break/>Ketoprofen 0.3&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> &#x02013; 65%<break/>Ketoprofen 1.0&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> &#x02013; 62%<break/>Ketoprofen 3.0&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> &#x02013; 53%<break/>Control &#x02013; 82%<break/>Proportion requiring fentanyl in first 2&#x000a0;h post-op</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Romsing <italic>et al</italic>. <xref rid="b42" ref-type="bibr">42</xref></td><td align="left" rowspan="1" colspan="1">Tonsillectomy &#x000b1;adenoidectomy<break/>Duration:<break/>61.6&#x000a0;&#x000b1;&#x000a0;22.0&#x000a0;mins</td><td align="left" rowspan="1" colspan="1">Ketorolac IV (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>40)<break/>Pre-op group:<break/>9.4&#x000a0;&#x000b1;&#x000a0;3.2&#x000a0;years<break/>post-op group:<break/>9.7&#x000a0;&#x000b1;&#x000a0;3.7&#x000a0;years</td><td align="left" rowspan="1" colspan="1">1.0&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> at induction (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>20)<break/>1.0&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> at end of surgery (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>20)</td><td align="left" rowspan="1" colspan="1">Saline (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>20)<break/>8.8&#x000a0;&#x000b1;&#x000a0;3.2&#x000a0;years</td><td align="left" rowspan="1" colspan="1">FentanylI<break/>V</td><td align="left" rowspan="1" colspan="1">BOLUS: 0.5 or 1.0&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup><break/>TRIGGER: nurse assessment or patient request</td><td align="left" rowspan="1" colspan="1">EQUIVOCAL (Pre-op 9%<xref ref-type="table-fn" rid="tf2-1">*</xref>, post-op 0%)<break/>Pre-op Ketorolac &#x02013; 2/55<break/>post-op Ketorolac &#x02013; 9/55<break/>Control &#x02013; 7/55<break/>Proportion requiring fentanyl in first 1.5&#x000a0;h post-op</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Nikane <italic>et al</italic>. 43</td><td align="left" rowspan="1" colspan="1">Adenoidectomy &#x000b1; myringotomy or tympanostomyDuration: not reported</td><td align="left" rowspan="1" colspan="1">Ketoprofen IV (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>80)<break/>38 (12&#x02013;111) months</td><td align="left" rowspan="1" colspan="1">1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> bolus + 1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> over 2&#x000a0;h</td><td align="left" rowspan="1" colspan="1">Saline (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>84)<break/>40 (10&#x02013;95) months</td><td align="left" rowspan="1" colspan="1">Fentanyl<break/>IV</td><td align="left" rowspan="1" colspan="1">BOLUS: 1&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup><break/>TRIGGER: Maunuksela &#x0003e;3</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf2-1">*</xref> (13%)<break/>Ketoprofen &#x02013; 51/80 &#x02013; 64%<break/>Control &#x02013; 65/84 &#x02013; 77%<break/>Proportion requiring fentanyl in PACU</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Bean-Lijewski <italic>et al</italic>. <xref rid="b44" ref-type="bibr">44</xref></td><td align="left" rowspan="1" colspan="1">Ilioinguinal or general surgery (day case)<break/>Duration: 93.0&#x000a0;&#x000b1;&#x000a0;21.2&#x000a0;mins</td><td align="left" rowspan="1" colspan="1">Ketorolac IV (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>29)<break/>4.0&#x000a0;&#x000b1;&#x000a0;2.2&#x000a0;years</td><td align="left" rowspan="1" colspan="1">0.75&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> at induction</td><td align="left" rowspan="1" colspan="1">Saline (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>28)<break/>4.2&#x000a0;&#x000b1;&#x000a0;3.0&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Pethidine (meperidine)<break/>IV</td><td align="left" rowspan="1" colspan="1">BOLUS: 0.5&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup><break/>TRIGGER: nurse assessment or patient request</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf2-1">*</xref> (46%)<break/>Ketorolac &#x02013; 13/29<break/>Control &#x02013; 26/28<break/>Proportion requiring pethidine in first 1&#x000a0;h post-op</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Sutters <italic>et al</italic>. <xref rid="b45" ref-type="bibr">45</xref></td><td align="left" rowspan="1" colspan="1">Tonsillectomy (day case)<break/>Duration not reported</td><td align="left" rowspan="1" colspan="1">Ketorolac IM (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>45)<break/>7.1&#x000a0;&#x000b1;&#x000a0;2.4&#x000a0;years</td><td align="left" rowspan="1" colspan="1">1.0&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> at end of surgery</td><td align="left" rowspan="1" colspan="1">Saline (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>42)<break/>7.1&#x000a0;&#x000b1;&#x000a0;2.2&#x000a0;years</td><td align="left" rowspan="1" colspan="1">FentanylI<break/>V</td><td align="left" rowspan="1" colspan="1">BOLUS:<break/>0.5&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup><break/>TRIGGER: nurse assessment in recovery</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf2-1">*</xref> (26%)<break/>Ketorolac &#x02013; 35.9&#x000a0;&#x000b1;&#x000a0;2.5<break/>Control &#x02013; 48.3&#x000a0;&#x000b1;&#x000a0;5.0<break/>Total dose microgram per group until day stay discharge, mean&#x000a0;&#x000b1;&#x000a0;<sc>sd</sc></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Watcha <italic>et al</italic>. <xref rid="b46" ref-type="bibr">46</xref></td><td align="left" rowspan="1" colspan="1">Adenotonsillectomy, moderate orthopedic or plastic surgery<break/>Duration:<break/>87&#x000a0;&#x000b1;&#x000a0;50&#x000a0;mins</td><td align="left" rowspan="1" colspan="1">Ketorolac IV (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>32)<break/>8.3&#x000a0;&#x000b1;&#x000a0;3.8&#x000a0;years</td><td align="left" rowspan="1" colspan="1">0.9&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> at induction</td><td align="left" rowspan="1" colspan="1">Saline (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>32)<break/>10.0&#x000a0;&#x000b1;&#x000a0;3.6&#x000a0;years</td><td align="left" rowspan="1" colspan="1">MorphineI<break/>V</td><td align="left" rowspan="1" colspan="1">BOLUS: 50&#x000a0;mcg&#x000b7;kg<sup>&#x02212;1</sup> in PACU<break/>TRIGGER: VAS&#x0003e; 60&#x000a0;mm or OPS &#x0003e;6</td><td align="left" rowspan="1" colspan="1">POSITIVE<xref ref-type="table-fn" rid="tf2-1">*</xref> (43%)<break/>Ketorolac &#x02013; 11/32<break/>Control &#x02013; 25/32<break/>Proportion requiring &#x0003e;1 morphine doses in PACU<break/><italic>Note: data only from ketorolac vs placebo arms</italic></td></tr></tbody></table><table-wrap-foot><fn id="tf2-1"><label>*</label><p>Positive, statistically significant opioid dose-sparing effect reported by authors; Negative, no statistically significant difference in opioid requirements.</p></fn><fn><p>PR, per rectum; IV, intravenous; IM, intramuscular.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p>Pain assessment and Secondary Outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Author (reference no.)</th><th align="left" rowspan="1" colspan="1">Age</th><th align="left" rowspan="1" colspan="1">Pain scale (range)</th><th align="left" rowspan="1" colspan="1">Pain score</th><th align="left" rowspan="1" colspan="1">Sedation</th><th align="left" rowspan="1" colspan="1">Respiratory depression</th><th align="left" rowspan="1" colspan="1">PONV</th><th align="left" rowspan="1" colspan="1">Pruritis</th><th align="left" rowspan="1" colspan="1">Urinary retention</th><th align="left" rowspan="1" colspan="1">Bleeding</th></tr></thead><tbody><tr><td align="left" colspan="10" rowspan="1">Group A</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hong <italic>et al</italic>. <xref rid="b26" ref-type="bibr">26</xref></td><td align="left" rowspan="1" colspan="1">0.5&#x02013;2&#x000a0;years</td><td align="left" rowspan="1" colspan="1">CHEOPS 4&#x02013;13</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Rugyte <italic>et al</italic>. <xref rid="b18" ref-type="bibr">18</xref></td><td align="left" rowspan="1" colspan="1">10&#x02013;15&#x000a0;years</td><td align="left" rowspan="1" colspan="1">VAS 0&#x02013;10</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">+</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Van der Marel <italic>et al</italic>. <xref rid="b17" ref-type="bibr">17</xref></td><td align="left" rowspan="1" colspan="1">0&#x02013;10&#x000a0;months</td><td align="left" rowspan="1" colspan="1">VAS 0&#x02013;10</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Munro <italic>et al</italic>. <xref rid="b19" ref-type="bibr">19</xref></td><td align="left" rowspan="1" colspan="1">11&#x02013;17&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Numerical 0 &#x02013; 10</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Morton <italic>et al</italic>. <xref rid="b20" ref-type="bibr">20</xref></td><td align="left" rowspan="1" colspan="1">5&#x02013;13&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Numerical 0 &#x02013; 3</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Sutters <italic>et al</italic>. <xref rid="b22" ref-type="bibr">22</xref></td><td align="left" rowspan="1" colspan="1">Mean 12.6&#x000a0;&#x000b1;&#x000a0;4&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Wong-Baker Faces 0&#x02013;5</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Sims <italic>et al</italic>. <xref rid="b21" ref-type="bibr">21</xref></td><td align="left" rowspan="1" colspan="1">&#x02265;7&#x000a0;years (mean 10&#x000a0;years)</td><td align="left" rowspan="1" colspan="1">VAS 0&#x02013;10</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td></tr><tr><td align="left" colspan="10" rowspan="1">Group B</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Antila <italic>et al</italic>. <xref rid="b25" ref-type="bibr">25</xref></td><td align="left" rowspan="1" colspan="1">9&#x02013;15&#x000a0;years</td><td align="left" rowspan="1" colspan="1">VAS 0 &#x02013; 10</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Oztekin <italic>et al</italic>. <xref rid="b24" ref-type="bibr">24</xref></td><td align="left" rowspan="1" colspan="1">5&#x02013;14&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Numerical 0 &#x02013; 10</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Vetter <italic>et al</italic>. <xref rid="b23" ref-type="bibr">23</xref></td><td align="left" rowspan="1" colspan="1">8&#x02013;16&#x000a0;years</td><td align="left" rowspan="1" colspan="1">VAS 0&#x02013;100</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" colspan="10" rowspan="1">Group C</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<xref rid="b27" ref-type="bibr">Mireskandari 27</xref></td><td align="left" rowspan="1" colspan="1">1.5&#x02013;5&#x000a0;years</td><td align="left" rowspan="1" colspan="1">CHEOPS</td><td align="left" rowspan="1" colspan="1">- combined vs placebo</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Kokki <italic>et al</italic>. <xref rid="b28" ref-type="bibr">28</xref></td><td align="left" rowspan="1" colspan="1">3&#x02013;16&#x000a0;years</td><td align="left" rowspan="1" colspan="1">VAS 0&#x02013;100</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Maunuksela <italic>et al</italic>. <xref rid="b29" ref-type="bibr">29</xref></td><td align="left" rowspan="1" colspan="1">4&#x02013;12&#x000a0;years</td><td align="left" rowspan="1" colspan="1">OPS 0 &#x02013; 9<break/>Numerical 0 &#x02013; 3</td><td align="left" rowspan="1" colspan="1">Observer =Patient -</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Maunuksela <italic>et al</italic>. <xref rid="b30" ref-type="bibr">30</xref></td><td align="left" rowspan="1" colspan="1">1&#x02013;16&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Numerical 0 &#x02013; 9<break/>Numerical 0 &#x02013; 3</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td></tr><tr><td align="left" colspan="10" rowspan="1">Group D</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hong <italic>et al</italic>. <xref rid="b31" ref-type="bibr">31</xref></td><td align="left" rowspan="1" colspan="1">1&#x02013;5&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Wong-Baker Faces 0&#x02013;5</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Dashti <italic>et al</italic>. <xref rid="b32" ref-type="bibr">32</xref></td><td align="left" rowspan="1" colspan="1">7&#x02013;15&#x000a0;years</td><td align="left" rowspan="1" colspan="1">VAS 1&#x02013;100</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Korpela <italic>et al</italic>. <xref rid="b33" ref-type="bibr">33</xref></td><td align="left" rowspan="1" colspan="1">1&#x02013;7&#x000a0;years</td><td align="left" rowspan="1" colspan="1">OPS 0&#x02013;9</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Sheeran <italic>et al</italic>. <xref rid="b34" ref-type="bibr">34</xref></td><td align="left" rowspan="1" colspan="1">&#x0003e;3&#x000a0;years</td><td align="left" rowspan="1" colspan="1">CHEOPS 4 &#x02013; 13</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Viitanen <italic>et al</italic>. <xref rid="b35" ref-type="bibr">35</xref></td><td align="left" rowspan="1" colspan="1">1&#x02013;6&#x000a0;years</td><td align="left" rowspan="1" colspan="1">OPS 0&#x02013;9</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Tuomilehto <italic>et al</italic>. <xref rid="b36" ref-type="bibr">36</xref></td><td align="left" rowspan="1" colspan="1">1&#x02013;9&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Modified Maunuksela scale 0&#x02013;10</td><td align="left" rowspan="1" colspan="1">-IV &#x0003c; placebo</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Bremerich <italic>et al</italic>. <xref rid="b37" ref-type="bibr">37</xref></td><td align="left" rowspan="1" colspan="1">1&#x02013;24&#x000a0;months</td><td align="left" rowspan="1" colspan="1">CHIPPS 0&#x02013;10</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Kokki <italic>et al</italic>. <xref rid="b38" ref-type="bibr">38</xref></td><td align="left" rowspan="1" colspan="1">1&#x02013;9&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Maunuksela 0&#x02013;10</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Tuomilehto <italic>et al</italic>. <xref rid="b47" ref-type="bibr">47</xref></td><td align="left" rowspan="1" colspan="1">1&#x02013;9</td><td align="left" rowspan="1" colspan="1">Maunuksela 0&#x02013;10</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Kokki <italic>et al</italic>. <xref rid="b40" ref-type="bibr">40</xref></td><td align="left" rowspan="1" colspan="1">1&#x02013;12&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Maunuksela 0&#x02013;10</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Korpela <italic>et al</italic>. <xref rid="b39" ref-type="bibr">39</xref></td><td align="left" rowspan="1" colspan="1">1&#x02013;11&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Observer NRS 0&#x02013;100</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Kokki <italic>et al</italic>. <xref rid="b41" ref-type="bibr">41</xref></td><td align="left" rowspan="1" colspan="1">1&#x02013;7&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Maunuksela 0&#x02013;10</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Romsing <italic>et al</italic>. <xref rid="b42" ref-type="bibr">42</xref></td><td align="left" rowspan="1" colspan="1">5&#x02013;15&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Poker Chip Tool 0&#x02013;4</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Nikanne <italic>et al</italic>. <xref rid="b43" ref-type="bibr">43</xref></td><td align="left" rowspan="1" colspan="1">1&#x02013;7&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Maunuksela 0&#x02013;10</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">+</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">+</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Bean-Lijewski <italic>et al</italic>. <xref rid="b44" ref-type="bibr">44</xref></td><td align="left" rowspan="1" colspan="1">1&#x02013;11&#x000a0;years</td><td align="left" rowspan="1" colspan="1">CHEOPS 4&#x02013;13</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Sutters <italic>et al</italic>. <xref rid="b45" ref-type="bibr">45</xref></td><td align="left" rowspan="1" colspan="1">7.1&#x000a0;&#x000b1;&#x000a0;2.4&#x000a0;years</td><td align="left" rowspan="1" colspan="1">Oucher 0&#x02013;5<break/>CHEOPS 4&#x02013;13</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Watcha <italic>et al</italic>. <xref rid="b46" ref-type="bibr">46</xref></td><td align="left" rowspan="1" colspan="1">5&#x02013;15&#x000a0;years</td><td align="left" rowspan="1" colspan="1">VAS 0&#x02013;100 OPS0&#x02013;9</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">X</td></tr></tbody></table><table-wrap-foot><fn><p>Pain score: &#x02018;=&#x02019; no significant difference in control and intervention groups, &#x02018;+&#x02019; higher pain score in intervention group compared with control, &#x02018;&#x02212;&#x02019; lower pain scores in intervention group compared with control, &#x02018;and &#x02018;X&#x02019; not reported.</p></fn><fn><p>Opioid-related adverse effects: &#x02018;=&#x02019; equal incidence in both control and intervention groups, &#x02018;+&#x02019; higher incidence in intervention group compared with control, &#x02018;&#x02212;&#x02019; lower incidence in intervention group compared with control, &#x02018;0&#x02019; indicate absence of this complication in both groups and &#x02018;X&#x02019; not reported.</p></fn><fn><p>CHEOPS, Children's Hospital of Eastern Ontario Pain Scale; VAS, Visual Analog Scale; OPS, Observer Pain Score; CHIPPS, Children's and Infants Postoperative Pain Scale; NRS, numerical rating scale.</p></fn></table-wrap-foot></table-wrap><p>Across the 31 studies, thirty-eight different drug groups were compared with placebo (Figure<xref ref-type="fig" rid="f1">1</xref>). Paracetamol and an NSAID were directly compared within four studies, with three also evaluating the combination of paracetamol and NSAID. Additional within study comparisons included dose-dependent effects of paracetamol <xref rid="b37" ref-type="bibr">37</xref>,<xref rid="b39" ref-type="bibr">39</xref> or ketoprofen <xref rid="b41" ref-type="bibr">41</xref>; different routes of administration of ketoprofen <xref rid="b36" ref-type="bibr">36</xref>,<xref rid="b38" ref-type="bibr">38</xref>,<xref rid="b47" ref-type="bibr">47</xref>; or administration of ketorolac at the beginning or end of surgery <xref rid="b42" ref-type="bibr">42</xref>. This increased the number of groups in which opioid consumption was measured to 48 treatment arms and 31 placebo controls (one per study) (Table<xref ref-type="table" rid="tbl4">4</xref>).</p><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><p>Summary of study groups and degree of opioid sparing</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Study design</th><th align="left" rowspan="1" colspan="1">Group A</th><th align="left" rowspan="1" colspan="1">Group B</th><th align="left" rowspan="1" colspan="1">Group C</th><th align="left" rowspan="1" colspan="1">Group D</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">No. of studies</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="1" colspan="1">No. of active treatment arms</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1">Negative arms</td><td align="left" rowspan="1" colspan="1">paracetamol (&#x000d7;2)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ketoprofen</td><td align="left" rowspan="1" colspan="1">paracetamol (&#x000d7;4)<break/>ketoprofen<break/>ketorolac<break/>rofecoxib</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive arms</td><td align="left" rowspan="1" colspan="1">paracetamol<break/>paracetamol&#x000a0;+&#x000a0;diclofenac<break/>diclofenac<break/>indomethacin<break/>ketoprofen<break/>ketorolac (&#x000d7;2)</td><td align="left" rowspan="1" colspan="1">diclofenac<break/>ketoprofen<break/>ketorolac</td><td align="left" rowspan="1" colspan="1">paracetamol<break/>paracetamol&#x000a0;+&#x000a0;diclofenac<break/>diclofenac<break/>ibuprofen<break/>indomethacin</td><td align="left" rowspan="1" colspan="1">paracetamol (&#x000d7;5)<break/>paracetamol&#x000a0;+&#x000a0;ibuprofen<break/>paracetamol&#x000a0;+&#x000a0;ketorolac<break/>ibuprofen<break/>ketoprofen (&#x000d7;10)<break/>ketorolac (&#x000d7;4)<break/>naproxen</td></tr><tr><td align="left" rowspan="1" colspan="1">% opioid reduction (mean) [95% CI]</td><td align="left" rowspan="1" colspan="1"><bold>31.6</bold><break/>[16.5&#x02013;46.6]</td><td align="left" rowspan="1" colspan="1"><bold>24.3</bold><break/>[&#x02212;1.7&#x02013;50.4]</td><td align="left" rowspan="1" colspan="1"><bold>24.5</bold><break/>[6.3&#x02013;42.6]</td><td align="left" rowspan="1" colspan="1"><bold>24.0</bold><break/>[16.4&#x02013;31.5]</td></tr></tbody></table><table-wrap-foot><fn><p>Bold values indicates mean % change in opioid consumption.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Opioid consumption</title><p>Significant decreases in opioid consumption by NSAID and/or paracetamol were reported in 21 of the 31 studies, four did not demonstrate any dose-sparing effects, and in six studies, both positive and negative results were reported for different treatment arms (Table<xref ref-type="table" rid="tbl1">1</xref> and <xref ref-type="table" rid="tbl2">2</xref>). Overall, positive effects were reported in 38 of 48 treatment arms (Figure<xref ref-type="fig" rid="f2">2</xref>).</p><fig id="f2" position="float"><label>Figure 2</label><caption><p>Percentage reduction in opioid requirements in pair-wise comparisons of mean opioid dose requirements in active treatment arms (paracetamol; NSAID; combination&#x000a0;=&#x000a0;NSAID&#x000a0;+&#x000a0;paracetamol) vs control/placebo. Studies reporting no statistically significant difference from control are designated as 0% reduction. Solid line&#x000a0;=&#x000a0;mean of NSAID arms; dotted line&#x000a0;=&#x000a0;mean of paracetamol arms. Treatment groups comprise Group A&#x000a0;=&#x000a0;PCA/NCA&#x000a0;+&#x000a0;study drug &#x02265;24&#x000a0;h; Group B&#x000a0;=&#x000a0;PCA/NCA&#x000a0;+&#x000a0;study drug &#x02264;6&#x000a0;h; Group C: intermittent opioid&#x000a0;+&#x000a0;study drug &#x02265;24&#x000a0;h; Group D&#x000a0;=&#x000a0;intermittent opioid&#x000a0;+&#x000a0;study drug &#x02264;6&#x000a0;h.</p></caption><graphic xlink:href="pan0023-0475-f2"/></fig><p>In Group A studies (seven studies with nine treatment arms), surgery was of moderate to major severity, and systemic opioid was available for immediate titration by the patient (PCA) or by nursing staff (NCA bolus plus background). In addition, study drug administration and evaluation continued for at least 24&#x000a0;h following surgery. Seven of nine treatment arms were positive. Two studies reported no significant benefit with addition of rectal paracetamol <xref rid="b17" ref-type="bibr">17</xref>,<xref rid="b20" ref-type="bibr">20</xref>. Overall, opioid dose requirements were reduced by 31.6% (95% CI: 16.5&#x02013;46.6) (Table<xref ref-type="table" rid="tbl4">4</xref>). Opioid sparing was reported in all Group B studies, with a mean reduction of 24.3%, but with wide variability, as only three studies were available.</p><p>Significant reduction in opioid dose was reported in five of six treatment arms in Group C (mean 24.5% 95% CI 6.3&#x02013;42.6) and in 23 of the 30 active treatment arms in Group D (mean 24%; 95% CI: 16.4&#x02013;31.5)(Table<xref ref-type="table" rid="tbl4">4</xref>). Overall, the majority of Group C/D studies demonstrated significant opioid sparing, but with much greater variability in reported results.</p></sec><sec><title>Paracetamol vs NSAID vs combination</title><p>A higher proportion of positive studies were reported in NSAID (27 of 31; 87%) than in paracetamol (7 of 13; 54%) treatment arms. Four studies included direct comparison of an NSAID and paracetamol. Rectal diclofenac (1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> intraoperative and 8 hrly for 24&#x000a0;h) produced opioid sparing, but by comparison, rectal paracetamol was less effective (40&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> intraoperative and 30&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> 8 hrly) <xref rid="b27" ref-type="bibr">27</xref> or showed no benefit (20&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> loading and 15&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> 6 hrly) <xref rid="b20" ref-type="bibr">20</xref>. Ibuprofen 15&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> PR was more effective than paracetamol 40&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> PR (27 vs 19% reduction) <xref rid="b35" ref-type="bibr">35</xref>, and preoperative oral administration of naproxen 10&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> was more effective than paracetamol 20&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> (19% vs nonsignificant difference) <xref rid="b33" ref-type="bibr">33</xref>. Positive opioid sparing by diclofenac (1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> 8 hrly PR) was further enhanced by addition of paracetamol 30&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> 8 hrly <xref rid="b27" ref-type="bibr">PR 27</xref>, but not by paracetamol 20&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> PR loading and 15&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> 6 hrly <xref rid="b20" ref-type="bibr">20</xref>. While both paracetamol 40&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> PR and ibuprofen 15&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> PR reduced opioid requirements following adenoidectomy, combining the two drugs provided no additional benefit <xref rid="b35" ref-type="bibr">35</xref>. A single combined dose of ketorolac and paracetamol markedly reduced postanesthesia care unit (PACU) opioid requirements, but effects of the individual drugs were not assessed <xref rid="b31" ref-type="bibr">31</xref>.</p></sec><sec><title>Within study comparisons: dose response and route of administration</title><p>Three studies included dose-response comparisons. Dose-dependent increases in opioid sparing in PACU were reported following 20, 40, and 60&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> rectal paracetamol (27 vs 54 vs 73%, respectively) <xref rid="b39" ref-type="bibr">39</xref>. Conversely, rectal paracetamol doses of 10, 20, or 40&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> had no significant effect in PACU following cleft palate repair <xref rid="b37" ref-type="bibr">37</xref>. Intravenous ketoprofen 0.3, 1, and 3&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> reduced the proportion of children requiring fentanyl for 2&#x000a0;h following adenoidectomy, with minimal dose-related differences (21, 24, and 35% reduction, respectively) <xref rid="b41" ref-type="bibr">41</xref>.</p><p>Administration of the same dose of ketoprofen by different routes demonstrated benefit with intravenous but not oral administration <xref rid="b47" ref-type="bibr">47</xref>, and similar degrees of opioid sparing following intravenous vs rectal <xref rid="b38" ref-type="bibr">38</xref> or intramuscular administration <xref rid="b36" ref-type="bibr">36</xref>. There have been no direct comparisons of paracetamol by different routes. <xref rid="b26" ref-type="bibr">Intravenous 26</xref> but not rectal <xref rid="b17" ref-type="bibr">17</xref>,<xref rid="b20" ref-type="bibr">20</xref> paracetamol reduced 24-h opioid requirements. Wide variability in individual plasma paracetamol concentrations was noted following rectal administration (0.8&#x02013;59.9&#x000a0;mg&#x000b7;l<sup>&#x02212;1</sup>) <xref rid="b17" ref-type="bibr">17</xref>.</p></sec><sec><title>Pain assessment and pain scores</title><p>All studies incorporated pain assessment, but by a range of different tools. Self-report included numerical rating (0&#x02013;3 or 0&#x02013;10), visual analog scales (0&#x02013;10 or 0&#x02013;100) or faces scales. Observer tools ranged from an overall numerical rating to composite measures of specific behavioral and physiological responses (e.g., Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) and COMFORT scales) (Table<xref ref-type="table" rid="tbl3">3</xref>).</p><p>In Group A and B studies, intravenous bolus opioid was triggered by the patient (PCA), who titrated themselves to similar pain scores in two of eight studies <xref rid="b20" ref-type="bibr">20</xref>,<xref rid="b21" ref-type="bibr">21</xref>. Six studies reported improved pain scores with addition of NSAID/paracetamol. Outcomes included different composite measures of pain (i.e., area under the pain intensity&#x02013;time graph for the first 24&#x000a0;h <xref rid="b18" ref-type="bibr">18</xref>, a main effect of treatment with repeated measures <sc>anova</sc> to 36&#x000a0;h <xref rid="b22" ref-type="bibr">22</xref>, overall pain score for first 12&#x000a0;h <xref rid="b23" ref-type="bibr">23</xref>). Others reported significant reductions in pain score only at some time points (i.e., the first 48&#x000a0;h <xref rid="b19" ref-type="bibr">19</xref>, the initial six postoperative hours <xref rid="b25" ref-type="bibr">25</xref> or the first hour in <xref rid="b24" ref-type="bibr">PACU 24</xref>).</p><p>In NCA studies, a background infusion plus opioid bolus administration by a nurse or trained parent following urologic surgery <xref rid="b26" ref-type="bibr">26</xref>, or by a nurse or investigator in intensive care after major abdominal or thoracic surgery <xref rid="b17" ref-type="bibr">17</xref>, resulted in effective titration to similar pain scores. In the latter study, a high proportion of patients were mechanically ventilated, and both Observer VAS and COMFORT scores were low in paracetamol and placebo groups <xref rid="b17" ref-type="bibr">17</xref>.</p><p>In Group C and D studies, opioid was available on an &#x02018;as needed&#x02019; or &#x02018;PRN&#x02019; basis. Nurse administration was triggered by a predetermined pain score using a formal assessment tool (16 studies) or global nursing assessment and patient request (five studies). Pain scores in treatment groups were reported to be significantly lower in the active treatment arm in 10 studies; reduced in some subgroups or on some subscales in 3; equivalent in 6; and were not reported in two studies (Table<xref ref-type="table" rid="tbl3">3</xref>).</p></sec><sec><title>Opioid-related adverse effects</title><p>Postoperative nausea and vomiting (PONV) was compared in 27 of 31 studies, with six study arms in five studies reporting a significant reduction in the paracetamol and/or NSAID group (Table<xref ref-type="table" rid="tbl3">3</xref>). The degree of opioid sparing tended to be greater (47%, 95% CI 22&#x02013;72) in treatment groups with less PONV when compared to studies with equivalent PONV (26%, 95% CI 20&#x02013;31). Within study comparisons found a significant reduction in the incidence of PONV with 40 and 60&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> PR, but not 20&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> which also had less effect on opioid requirement <xref rid="b39" ref-type="bibr">39</xref>. Preoperative, but not postoperative, ketorolac reduced both opioid requirement and the number of children vomiting following tonsillectomy <xref rid="b42" ref-type="bibr">42</xref>.</p><p>Ten studies noted no difference in significant adverse respiratory effects, reported as either a lack of respiratory depression or no difference in respiratory rate or episodes of desaturation. Sedation was assessed in 17 of 31 studies: 14 reported no difference, and three studies with positive opioid sparing also reported less sedation in the active treatment group. The incidence of oversedation (defined as Ramsay sedation score &#x0003e;4 on 8-point scale) was reduced when paracetamol <xref rid="b26" ref-type="bibr">26</xref> or ketorolac plus paracetamol <xref rid="b31" ref-type="bibr">31</xref> was used with fentanyl NCA; and &#x02018;somnolence&#x02019; and IV fentanyl bolus use in PACU was less frequent with addition of ketoprofen <xref rid="b43" ref-type="bibr">43</xref>.</p><p>No difference in adverse urinary effects (i.e., need for catheterization or difficulty voiding) was noted in nine studies, but fewer children required a urinary catheter following orthopedic surgery if they received IV ketorolac (1 of 25 vs 7 of 25 in the control group) <xref rid="b23" ref-type="bibr">23</xref>. Six studies recorded pruritus, but there were no differences between treatment and control groups.</p></sec><sec><title>NSAID/paracetamol adverse effects</title><p>No cases of accidental overdose or toxicity related to paracetamol were reported.</p><p>Alteration in bleeding was the main potential NSAID adverse effect evaluated, particularly as many studies were conducted in children undergoing tonsillectomy. The incidence or degree of perioperative bleeding was reported in 21 NSAID studies: seven each of ketoprofen or ketorolac, two of diclofenac or ibuprofen, and single studies of naproxen or rofecoxib. Bleeding following paracetamol was assessed in three studies, of which two included an NSAID treatment arm. Methods for reporting this outcome varied and included the following: direct measurements of intraoperative blood loss or postoperative blood loss in drains; graded but subjective assessments of intraoperative blood loss by the surgeon; rate of re-operation/interventions to control increased bleeding; or statements that no patients had significant bleeding. Following tonsillectomy and/or adenoidectomy, measured perioperative blood loss was not increased following ketorolac 1&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup>
<xref rid="b42" ref-type="bibr">42</xref> or ketoprofen <xref rid="b25" ref-type="bibr">25</xref>,<xref rid="b28" ref-type="bibr">28</xref>. Graded assessment of blood loss by the surgeon found no increase in intraoperative bleeding with ketorolac <xref rid="b45" ref-type="bibr">45</xref>, ibuprofen <xref rid="b35" ref-type="bibr">35</xref>, or ketoprofen <xref rid="b25" ref-type="bibr">25</xref>,<xref rid="b36" ref-type="bibr">36</xref>,<xref rid="b38" ref-type="bibr">38</xref>,<xref rid="b41" ref-type="bibr">41</xref>. Although not quantified, no cases of increased bleeding were reported following rofecoxib <xref rid="b34" ref-type="bibr">34</xref>, naproxen <xref rid="b33" ref-type="bibr">33</xref>, or paracetamol <xref rid="b32" ref-type="bibr">32</xref>,<xref rid="b33" ref-type="bibr">33</xref>. In one study, the rate of &#x02018;more than normal&#x02019; bleeding was greater following ketoprofen (12 of 80 vs 3 of 84; <italic>P</italic>&#x000a0;=&#x000a0;0.037), but no patients required re-operation <xref rid="b43" ref-type="bibr">43</xref>. Cases of bleeding requiring reoperation were reported in both placebo and/or NSAID groups. Two patients were excluded from analysis following ketorolac as they required an immediate return to the operating theater to control surgical bleeding <xref rid="b42" ref-type="bibr">42</xref>; one patient was withdrawn due to bleeding at 5&#x000a0;h following ketoprofen <xref rid="b18" ref-type="bibr">18</xref>; two patients required diathermy under local anesthesia at 4 or 26&#x000a0;h following ketoprofen <xref rid="b28" ref-type="bibr">28</xref>; and one patient required nasopharyngeal packing overnight following diclofenac <xref rid="b24" ref-type="bibr">24</xref>. Bleeding requiring surgical intervention was also reported in three patients given placebo <xref rid="b24" ref-type="bibr">24</xref>,<xref rid="b25" ref-type="bibr">25</xref>,<xref rid="b46" ref-type="bibr">46</xref>.</p><p>Measured blood loss did not differ from control groups during spinal fusion with ketorolac <xref rid="b19" ref-type="bibr">19</xref> or ophthalmic, general or orthopedic surgery with ibuprofen <xref rid="b29" ref-type="bibr">29</xref>. No significant episodes of bleeding were reported with diclofenac for cleft palate repair <xref rid="b27" ref-type="bibr">27</xref>, or with ketorolac for orthopedic <xref rid="b23" ref-type="bibr">23</xref> or day case general surgery <xref rid="b44" ref-type="bibr">44</xref>, despite a greater increase in measured bleeding time (53.4&#x000a0;&#x000b1;&#x000a0;74.8&#x000a0;s) in the latter study.</p></sec><sec><title>Patient/parent satisfaction</title><p>Relatively few studies evaluated overall satisfaction with treatment, and none included patient satisfaction as an outcome. Higher levels of parental satisfaction in the active treatment arm either during the in-hospital stay <xref rid="b26" ref-type="bibr">26</xref>,<xref rid="b31" ref-type="bibr">31</xref> or during both the time in hospital and following discharge <xref rid="b34" ref-type="bibr">34</xref> were reported. No comparison was made with patient satisfaction, but these studies enrolled infants <xref rid="b26" ref-type="bibr">26</xref>,<xref rid="b31" ref-type="bibr">31</xref> or young children (&#x0003e;3&#x000a0;years; mean 7&#x000a0;years) <xref rid="b34" ref-type="bibr">34</xref>.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Recommendations to use multimodal analgesic therapy for perioperative pain management in children <xref rid="b3" ref-type="bibr">3</xref>,<xref rid="b7" ref-type="bibr">7</xref> are supported by this qualitative systematic review. Across 31 studies, 38 of 48 active treatment arms reported a statistically significant reduction in opioid requirements with co-administration of NSAID and/or paracetamol in pair-wise comparisons with a placebo group. However, potential publication bias against negative studies cannot be excluded. Evidence for a clinical advantage in terms of improved pain scores or a reduction in adverse effects was less robust. However, variability in study design, method of opioid delivery, duration of study drug administration, and reported outcome measures had an impact on the likelihood and degree of positive findings.</p><sec><title>Opioid dose requirements</title><p>Opioid-sparing effects with perioperative NSAIDs and paracetamol have been well documented in meta-analyses of adult studies <xref rid="b10" ref-type="bibr">10</xref>,<xref rid="b11" ref-type="bibr">11</xref>,<xref rid="b48" ref-type="bibr">48</xref>, using a standardized measure of opioid dose (24&#x000a0;h total PCA morphine consumption) <xref rid="b10" ref-type="bibr">10</xref>[additional details in <xref rid="b8" ref-type="bibr">8</xref>]. In the current pediatric series, all studies that evaluated cumulative PCA morphine dose (mcg&#x000b7;kg<sup>&#x02212;1</sup>&#x000b7;day<sup>&#x02212;1</sup> in children aged at least 5&#x000a0;years) reported significant reductions in opioid requirements in the first 24&#x000a0;h by regular doses of NSAID <xref rid="b18" ref-type="bibr">18</xref>&#x02013;<xref rid="b22" ref-type="bibr">22</xref>,<xref rid="b25" ref-type="bibr">25</xref>) and in the early postoperative period by a single dose of diclofenac <xref rid="b24" ref-type="bibr">24</xref> or ketorolac <xref rid="b23" ref-type="bibr">23</xref>. These studies were also included in a meta-analysis of 28 pediatric studies, which calculated the standardized mean difference in opioid requirements for individual trials, and reported significant opioid sparing in PACU and during the first 24&#x000a0;h by NSAID <xref rid="b13" ref-type="bibr">13</xref>. We have also evaluated studies of perioperative paracetamol and found more variable results: rectal paracetamol did not reduce PCA <xref rid="b20" ref-type="bibr">20</xref> or NCA <xref rid="b17" ref-type="bibr">17</xref> opioid requirements, but IV paracetamol reduced NCA opioid requirements in children aged 6&#x02013;24&#x000a0;months <xref rid="b26" ref-type="bibr">26</xref>.</p><p>Variable methodology in pediatric analgesic studies influences the sensitivity for detecting differences and the ability to combine data across studies <xref rid="b14" ref-type="bibr">14</xref>,<xref rid="b49" ref-type="bibr">49</xref>. Michelet and colleagues <xref rid="b13" ref-type="bibr">13</xref> also noted significant heterogeneity, but benefit with NSAID was maintained in subgroup analyses of the effects of surgery (adenotonsillectomy vs orthopedic or general surgery) and timing of administration (intra- vs postoperative NSAID) <xref rid="b13" ref-type="bibr">13</xref>. In the current studies, the degree of opioid sparing tended to be higher and more consistent when opioid was readily available for titration (i.e., PCA or NCA) and repeated doses of study drug were given (i.e., Group A design). Studies with opioid available on an intermittent &#x02018;PRN&#x02019; basis and evaluating the effect of a single dose of NSAID/paracetamol (i.e., Group D design) also reported significant opioid sparing, but there was much greater variability in the degree of difference and in the outcome being evaluated. Many were conducted following surgery with relatively low analgesic requirements, and group data such as the proportion of patients requiring opioid in PACU, rather than individual dose requirements, were the primary outcomes. Some statistically significant differences may have limited clinical significance (e.g., mean differences of less than one dose per patient). In addition, the duration of follow-up was often limited to time in the PACU or the first 1&#x02013;2 postoperative hours, with only one study reporting a reduction in analgesic requirements following discharge <xref rid="b39" ref-type="bibr">39</xref>. Reduction in PACU opioid requirements with NSAID has also been confirmed by meta-analysis <xref rid="b13" ref-type="bibr">13</xref> and while reducing early postoperative pain is clearly important, the greater clinical challenge may be to determine whether this translates into reduced analgesic requirements or improved analgesia following discharge. Recent studies confirm that many children experience significant levels of pain at home <xref rid="b50" ref-type="bibr">50</xref>,<xref rid="b51" ref-type="bibr">51</xref>, and provision of adequate analgesia following discharge remains an unmet need.</p></sec><sec><title>Analgesic efficacy</title><p>Recruiting children across wide age ranges necessitates use of different measurement tools, and standardized use of validated measures has been advocated <xref rid="b52" ref-type="bibr">52</xref> to improve comparison across studies. The observer and self-report pain assessment tools used in the reviewed studies have variable numbers of choices and different linear/ratio characteristics, making it difficult to compare absolute changes in pain &#x02018;score&#x02019; or intensity or to evaluate an overall change over time. Pain intensity is often not evaluated in adult analyses as it is assumed that patients will titrate themselves to similar levels of analgesia <xref rid="b10" ref-type="bibr">10</xref>,<xref rid="b11" ref-type="bibr">11</xref>; but one analysis found pain intensity was reduced at 24&#x000a0;h by multidose NSAID, but not single-dose NSAID or paracetamol <xref rid="b48" ref-type="bibr">48</xref>. In the pediatric meta-analysis, addition of NSAIDs to opioids reduced pain intensity in the PACU but not the first 24&#x000a0;h <xref rid="b13" ref-type="bibr">13</xref>. In 6 of the 8 PCA studies reviewed here, pain scores were lower in the active treatment arms, despite these older children being able to &#x02018;self-titrate&#x02019; their analgesia. It is possible children may tolerate higher levels of pain to avoid opioid-related PONV, as has been suggested in adult studies <xref rid="b12" ref-type="bibr">12</xref>. Intermittent opioid administration by a nurse can have less flexible dosing schedules, additional time constraints, and is reliant on the frequency and sensitivity of pain assessment. Nine of 12 Group D studies reported lower pain scores, suggesting that intermittent dosing in the early postoperative period was less effective for titrating analgesia in the placebo groups.</p><p>Analgesic trials in children can pose ethical challenges, particularly in the use of placebo control groups <xref rid="b53" ref-type="bibr">53</xref>. Using a rescue-analgesic design with analgesic sparing as a surrogate efficacy endpoint incorporates the scientific and regulatory advantages of placebo-controlled trials, while ensuring children have analgesia available for immediate titration <xref rid="b53" ref-type="bibr">53</xref>. All studies included in this analysis had opioid available for titration postoperatively, either by PCA/NCA or by intermittent bolus. In the majority of studies, both NSAID/paracetamol and placebo treatment arms also received standardized intraoperative opioid and/or local anesthetic infiltration. In some early Group C/D studies, intraoperative analgesia was limited to nitrous oxide alone <xref rid="b29" ref-type="bibr">29</xref>,<xref rid="b30" ref-type="bibr">30</xref>,<xref rid="b39" ref-type="bibr">39</xref>,<xref rid="b44" ref-type="bibr">44</xref>&#x02013;<xref rid="b46" ref-type="bibr">46</xref>. Opioid was available for titration in PACU, and all studies reported significantly higher analgesic requirements in the placebo group <xref rid="b29" ref-type="bibr">29</xref>,<xref rid="b30" ref-type="bibr">30</xref>,<xref rid="b39" ref-type="bibr">39</xref>,<xref rid="b44" ref-type="bibr">44</xref>&#x02013;<xref rid="b46" ref-type="bibr">46</xref>. Differences in intraoperative analgesia may also contribute to a cross-study variability in opioid sparing, particularly when assessment is limited to the first few postoperative hours.</p></sec><sec><title>Opioid-related adverse effects</title><p>Although statistically significant reductions in opioid requirements demonstrate analgesic benefit, clinical benefit is enhanced if there is also a reduction in opioid-related adverse effects. Individual studies are rarely powered for these secondary outcomes and definitions or thresholds for reporting adverse effects vary across studies. Postoperative vomiting is an important cause of morbidity, a leading concern for parents and patients, and may require readmission <xref rid="b54" ref-type="bibr">54</xref>,<xref rid="b55" ref-type="bibr">55</xref>. In the first 24 postoperative hours, NSAIDs had a similar impact on PONV in meta-analyses of adult (odds ratio 0.7, 95% CI 0.53&#x02013;0.88) <xref rid="b10" ref-type="bibr">10</xref> and pediatric (odds ratio 0.75, 95% CI 0.57&#x02013;0.99) <xref rid="b13" ref-type="bibr">13</xref> studies. In addition to patient (i.e., age, gender) and anesthetic factors, the type of surgery can have a significant effect. Many pediatric studies have been conducted following tonsillectomy, which has a high rate of PONV, and NSAIDs had a greater impact in this subgroup <xref rid="b13" ref-type="bibr">13</xref>. There have been insufficient studies to specifically evaluate PONV in other high-risk surgical groups, such as strabismus, although beneficial effects of NSAID on both opioid sparing and vomiting have been reported <xref rid="b40" ref-type="bibr">40</xref>. Although some studies evaluated the number of episodes of vomiting in individual children <xref rid="b28" ref-type="bibr">28</xref>,<xref rid="b40" ref-type="bibr">40</xref>, the majority of studies reported the incidence of vomiting within treatment arms, and it was not possible to differentiate effects on the frequency or severity of vomiting. Other opioid-related adverse effects, such as urinary retention and pruritus are less common, are less likely to be reported in individual studies, and no significant differences were reported in a meta-analysis <xref rid="b13" ref-type="bibr">13</xref>.</p><p>Respiratory depression is the most feared adverse effect of opioids, with an incidence in large pediatric audits (&#x0003e;10&#x000a0;000 patients) of 0.13% with opioid via continuous infusion, PCA, or NCA <xref rid="b1" ref-type="bibr">1</xref> and 0.4% with opioid NCA in a younger population <xref rid="b2" ref-type="bibr">2</xref>. Clinical trials are not powered to evaluate this rare outcome and often exclude patients shown to be at highest risk (i.e., neonates, particularly those born preterm, and patients with comorbid conditions such as cardiorespiratory disease and neurodevelopmental impairment) <xref rid="b1" ref-type="bibr">1</xref>,<xref rid="b2" ref-type="bibr">2</xref>. Increased sedation, which can be a more reliable indicator of impending respiratory depression, was noted in some placebo groups, but was not sufficient to be associated with respiratory depression or oxygen desaturation. <xref rid="b26" ref-type="bibr">26</xref>,<xref rid="b31" ref-type="bibr">31</xref>,<xref rid="b43" ref-type="bibr">43</xref>.</p></sec><sec><title>Type of surgery</title><p>Studies included here and in previous analyses of perioperative opioid dose requirements in children <xref rid="b7" ref-type="bibr">7</xref>,<xref rid="b13" ref-type="bibr">13</xref> include patients undergoing a range of different surgeries, with variable perioperative analgesic requirements. When opioid requirements were relatively high and administration via NCA or PCA was required, results were less variable and the ability to detect significant differences with co-administration of NSAIDs was enhanced. NSAIDs may have specific efficacy against bone pain, and one within study comparison showed benefit with ibuprofen following orthopedic but not general surgery <xref rid="b29" ref-type="bibr">29</xref>. Tonsillectomy not only has an impact on potential opioid-related adverse effects such as PONV, but analgesic benefits must also be weighed against the potential for NSAID-induced bleeding. Cases of post-tonsillectomy bleeding were noted in both NSAID and placebo groups but the number requiring intervention was small. Meta-analyses of pediatric studies have concluded that the risk of bleeding requiring reoperation is not increased by diclofenac for acute pain <xref rid="b56" ref-type="bibr">56</xref> or NSAIDs following tonsillectomy <xref rid="b57" ref-type="bibr">57</xref>.</p></sec><sec><title>Comparison of study drugs</title><p>There is currently insufficient data to determine the relative efficacy of paracetamol or different NSAIDs, and the dose equivalence of different preparations at different ages is not well-established. Overall, the proportion of positive studies was lower with paracetamol, and adult analyses also suggest a greater degree of opioid sparing with NSAIDs vs paracetamol <xref rid="b10" ref-type="bibr">10</xref>. However, pediatric studies may also be confounded by inadequate paracetamol dosing and variability in absorption, particularly when given by the rectal route <xref rid="b17" ref-type="bibr">17</xref>. Within study comparisons found dose-dependent increases in opioid sparing with higher rectal paracetamol dose <xref rid="b37" ref-type="bibr">37</xref>,<xref rid="b39" ref-type="bibr">39</xref>. The time to peak plasma concentration varies with the rectal preparation, but can exceed 2&#x000a0;h <xref rid="b58" ref-type="bibr">58</xref>,<xref rid="b59" ref-type="bibr">59</xref>. In addition, the equilibration half-life (t<sub>eq</sub>) for the analgesic effect compartment is over 50&#x000a0;min, which further delays time to maximum analgesia <xref rid="b60" ref-type="bibr">60</xref>. As a result, an adequate effect site concentration may not be achieved following administration of single doses for relatively brief surgical procedures with evaluation in PACU; a design commonly utilized in the studies classified here as Group D, which show wide variability in reported opioid sparing and the greatest number of negative paracetamol studies. Intravenous paracetamol was beneficial in 2 included studies <xref rid="b26" ref-type="bibr">26</xref>,<xref rid="b31" ref-type="bibr">31</xref> and has recently been reported to reduce opioid requirements in neonates and infants following major surgery <xref rid="b61" ref-type="bibr">61</xref>. Recent pharmacokinetic analyses provide further data regarding appropriate dose schedules for intravenous paracetamol <xref rid="b62" ref-type="bibr">62</xref>,<xref rid="b63" ref-type="bibr">63</xref>.</p><p>Combining an NSAID and paracetamol produced variable benefit in individual studies. Using time-effect profiles at different doses, a recent simulation with paracetamol and ibuprofen suggests analgesic benefit with this combination is more likely to be seen with modest doses of drug and at time points beyond PACU (i.e., &#x0003e;2&#x000a0;h) <xref rid="b64" ref-type="bibr">64</xref>. High doses of NSAID approach a maximum or ceiling effect, and little additional benefit may be gained by adding paracetamol <xref rid="b64" ref-type="bibr">64</xref>. Additive analgesia with paracetamol and NSAID has been demonstrated in adults with acute pain <xref rid="b9" ref-type="bibr">9</xref>,<xref rid="b16" ref-type="bibr">16</xref>,<xref rid="b65" ref-type="bibr">65</xref>, and although co-administration did not significantly alter opioid requirements, meta-analysis of pediatric studies reported a further reduction in pain intensity during the first 24&#x000a0;h when regular paracetamol was added to NSAID <xref rid="b13" ref-type="bibr">13</xref>.</p></sec><sec><title>Limitations and future directions</title><p>The current systematic review is limited to a qualitative analysis; however, findings are consistent with a recent meta-analysis which evaluated the impact of NSAID on postoperative opioid requirements in children <xref rid="b13" ref-type="bibr">13</xref>. This meta-analysis provides more detailed quantification of the degree (i.e., standardized mean difference) in opioid requirement, and by combining data for secondary outcomes, such as PONV, can better evaluate effects for which individual studies are inadequately powered. However, significant heterogeneity is often seen in pediatric analgesic studies, with variability in design, study population, and outcome measures. Qualitative reviews can provide further information about which clinical populations are most likely to benefit from the intervention and highlight areas requiring further research. There is an ongoing need for more uniform use of validated pain scores and outcome measures <xref rid="b52" ref-type="bibr">52</xref> to facilitate comparison and combination of data from different trials. Standardized definitions and reporting of adverse effects or clinical endpoints such as PONV, pruritus, and sedation would also enhance evaluation of relative risks and benefits. Further quantification of clinically significant benefits is likely to require much larger or multi-center studies that are sufficiently powered to detect differences in adverse effects rather than just differences in opioid consumption <xref rid="b10" ref-type="bibr">10</xref> and/or that have more prolonged follow-up that includes evaluation of pain and function following discharge after short-stay or day case surgery.</p></sec></sec><sec sec-type="conclusion"><title>Conclusion</title><p>NSAIDs and/or paracetamol reduce perioperative opioid requirements in children, and positive effects are most consistently seen when opioid requirements are relatively high and titrated by NCA or PCA. The degree of clinically significant benefit in terms of improved analgesic benefit or reduction in opioid-related adverse effects varies across studies, and there is currently insufficient data to compare the relative efficacy of different drugs. The doses of NSAIDs and/or paracetamol utilized in these trials were not associated with any additional adverse effects. These data provide further support for use of multimodal analgesia for perioperative pain in children.</p></sec></body><back><ack><p>This work was supported in part by funding from a Royal College of Anaesthetists/British Journal of Anaesthesia project grant (SMW).</p></ack><sec><title>Conflict of interest</title><p>No conflicts of interest declared.</p></sec><ref-list><title>References</title><ref id="b1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morton</surname><given-names>NS</given-names></name><name><surname>Errera</surname><given-names>A</given-names></name></person-group><article-title>APA national audit of pediatric opioid infusions</article-title><source>Pediatr Anesth</source><year>2010</year><volume>20</volume><fpage>119</fpage><lpage>125</lpage></element-citation></ref><ref id="b2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>RF</given-names></name><name><surname>Lloyd-Thomas</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nurse-controlled analgesia (NCA) following major surgery in 10&#x000a0;000 patients in a children's hospital</article-title><source>Pediatr Anesth</source><year>2010</year><volume>20</volume><fpage>126</fpage><lpage>134</lpage></element-citation></ref><ref id="b3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>RF</given-names></name><name><surname>Carter</surname><given-names>B</given-names></name><name><surname>Curry</surname><given-names>J</given-names></name><etal/></person-group><article-title>Good practice in postoperative and procedural pain. A guideline from the association of paediatric anaesthetists of Great Britain and Ireland</article-title><source>Pediatr Anesth</source><year>2012</year><volume>22</volume><fpage>1</fpage><lpage>79</lpage></element-citation></ref><ref id="b4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>J</given-names></name><name><surname>Liley</surname><given-names>A</given-names></name><name><surname>Anderson</surname><given-names>BJ</given-names></name></person-group><article-title>The relationship between age and morphine infusion rate in children</article-title><source>Pediatr Anesth</source><year>2013</year><volume>23</volume><fpage>40</fpage><lpage>44</lpage></element-citation></ref><ref id="b5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouwmeester</surname><given-names>NJ</given-names></name><name><surname>Hop</surname><given-names>WC</given-names></name><name><surname>van Dijk</surname><given-names>M</given-names></name><etal/></person-group><article-title>Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism</article-title><source>Intensive Care Med</source><year>2003</year><volume>29</volume><fpage>2009</fpage><lpage>2015</lpage><pub-id pub-id-type="pmid">12897995</pub-id></element-citation></ref><ref id="b6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lonnqvist</surname><given-names>PA</given-names></name><name><surname>Morton</surname><given-names>NS</given-names></name></person-group><article-title>Postoperative analgesia in infants and children</article-title><source>Br J Anaesth</source><year>2005</year><volume>95</volume><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">15668207</pub-id></element-citation></ref><ref id="b7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duedahl</surname><given-names>TH</given-names></name><name><surname>Hansen</surname><given-names>EH</given-names></name></person-group><article-title>A qualitative systematic review of morphine treatment in children with postoperative pain</article-title><source>Pediatr Anesth</source><year>2007</year><volume>17</volume><fpage>756</fpage><lpage>774</lpage></element-citation></ref><ref id="b8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDaid</surname><given-names>C</given-names></name><name><surname>Maund</surname><given-names>E</given-names></name><name><surname>Rice</surname><given-names>S</given-names></name><etal/></person-group><article-title>Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the reduction of morphine-related side effects after major surgery: a systematic review</article-title><source>Health Technol Assess</source><year>2010</year><volume>14</volume><fpage>1</fpage><lpage>153</lpage><comment>iii-iv</comment><pub-id pub-id-type="pmid">20346263</pub-id></element-citation></ref><ref id="b9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>CK</given-names></name><name><surname>Seymour</surname><given-names>RA</given-names></name><name><surname>Lirk</surname><given-names>P</given-names></name><etal/></person-group><article-title>Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain</article-title><source>Anesth Analg</source><year>2010</year><volume>110</volume><fpage>1170</fpage><lpage>1179</lpage><pub-id pub-id-type="pmid">20142348</pub-id></element-citation></ref><ref id="b10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maund</surname><given-names>E</given-names></name><name><surname>McDaid</surname><given-names>C</given-names></name><name><surname>Rice</surname><given-names>S</given-names></name><etal/></person-group><article-title>Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: a systematic review</article-title><source>Br J Anaesth</source><year>2011</year><volume>106</volume><fpage>292</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">21285082</pub-id></element-citation></ref><ref id="b11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remy</surname><given-names>C</given-names></name><name><surname>Marret</surname><given-names>E</given-names></name><name><surname>Bonnet</surname><given-names>F</given-names></name></person-group><article-title>Effects of acetaminophen on morphine side-effects and consumption after major surgery: meta-analysis of randomized controlled trials</article-title><source>Br J Anaesth</source><year>2005</year><volume>94</volume><fpage>505</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">15681586</pub-id></element-citation></ref><ref id="b12"><label>12</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Macintyre</surname><given-names>PE</given-names></name><name><surname>Schug</surname><given-names>SA</given-names></name><name><surname>Scott</surname><given-names>DA</given-names></name><etal/></person-group><source>APM:SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine. Acute Pain Management: Scientific Evidence</source><year>2010</year><edition>3rd edn</edition><publisher-loc>Melbourne</publisher-loc><publisher-name>ANZCA &#x00026; FPM</publisher-name></element-citation></ref><ref id="b13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michelet</surname><given-names>D</given-names></name><name><surname>Andreu-Gallien</surname><given-names>J</given-names></name><name><surname>Bensalah</surname><given-names>T</given-names></name><etal/></person-group><article-title>A meta-analysis of the use of nonsteroidal antiinflammatory drugs for pediatric postoperative pain</article-title><source>Anesth Analg</source><year>2012</year><volume>114</volume><fpage>393</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">22104069</pub-id></element-citation></ref><ref id="b14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamunen</surname><given-names>K</given-names></name><name><surname>Kontinen</surname><given-names>V</given-names></name></person-group><article-title>Systematic review on analgesics given for pain following tonsillectomy in children</article-title><source>Pain</source><year>2005</year><volume>117</volume><fpage>40</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">16109456</pub-id></element-citation></ref><ref id="b15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jadad</surname><given-names>AR</given-names></name><name><surname>Moore</surname><given-names>RA</given-names></name><name><surname>Carroll</surname><given-names>D</given-names></name><etal/></person-group><article-title>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</article-title><source>Control Clin Trials</source><year>1996</year><volume>17</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">8721797</pub-id></element-citation></ref><ref id="b16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyllested</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Pedersen</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review</article-title><source>Br J Anaesth</source><year>2002</year><volume>88</volume><fpage>199</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">11878654</pub-id></element-citation></ref><ref id="b17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Marel</surname><given-names>CD</given-names></name><name><surname>Peters</surname><given-names>JW</given-names></name><name><surname>Bouwmeester</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Rectal acetaminophen does not reduce morphine consumption after major surgery in young infants</article-title><source>Br J Anaesth</source><year>2007</year><volume>98</volume><fpage>372</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">17284514</pub-id></element-citation></ref><ref id="b18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rugyte</surname><given-names>D</given-names></name><name><surname>Kokki</surname><given-names>H</given-names></name></person-group><article-title>Intravenous ketoprofen as an adjunct to patient-controlled analgesia morphine in adolescents with thoracic surgery: a placebo controlled double-blinded study</article-title><source>Eur J Pain</source><year>2007</year><volume>11</volume><fpage>694</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">17185016</pub-id></element-citation></ref><ref id="b19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munro</surname><given-names>HM</given-names></name><name><surname>Walton</surname><given-names>SR</given-names></name><name><surname>Malviya</surname><given-names>S</given-names></name><etal/></person-group><article-title>Low-dose ketorolac improves analgesia and reduces morphine requirements following posterior spinal fusion in adolescents</article-title><source>Can J Anaesth</source><year>2002</year><volume>49</volume><fpage>461</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">11983659</pub-id></element-citation></ref><ref id="b20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morton</surname><given-names>NS</given-names></name><name><surname>O'Brien</surname><given-names>K</given-names></name></person-group><article-title>Analgesic efficacy of paracetamol and diclofenac in children receiving PCA morphine</article-title><source>Br J Anaesth</source><year>1999</year><volume>82</volume><fpage>715</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">10536549</pub-id></element-citation></ref><ref id="b21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sims</surname><given-names>C</given-names></name><name><surname>Johnson</surname><given-names>CM</given-names></name><name><surname>Bergesio</surname><given-names>R</given-names></name><etal/></person-group><article-title>Rectal indomethacin for analgesia after appendicectomy in children</article-title><source>Anaesth Intensive Care</source><year>1994</year><volume>22</volume><fpage>272</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">8085623</pub-id></element-citation></ref><ref id="b22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutters</surname><given-names>KA</given-names></name><name><surname>Shaw</surname><given-names>BA</given-names></name><name><surname>Gerardi</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Comparison of morphine patient-controlled analgesia with and without ketorolac for postoperative analgesia in pediatric orthopedic surgery</article-title><source>Am J Orthop (Belle Mead NJ)</source><year>1999</year><volume>28</volume><fpage>351</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">10401901</pub-id></element-citation></ref><ref id="b23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vetter</surname><given-names>TR</given-names></name><name><surname>Heiner</surname><given-names>EJ</given-names></name></person-group><article-title>Intravenous ketorolac as an adjuvant to pediatric patient-controlled analgesia with morphine</article-title><source>J Clin Anesth</source><year>1994</year><volume>6</volume><fpage>110</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">8204227</pub-id></element-citation></ref><ref id="b24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oztekin</surname><given-names>S</given-names></name><name><surname>Hepaguslar</surname><given-names>H</given-names></name><name><surname>Kar</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Preemptive diclofenac reduces morphine use after remifentanil-based anaesthesia for tonsillectomy</article-title><source>Paediatr Anaesth</source><year>2002</year><volume>12</volume><fpage>694</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">12472706</pub-id></element-citation></ref><ref id="b25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antila</surname><given-names>H</given-names></name><name><surname>Manner</surname><given-names>T</given-names></name><name><surname>Kuurila</surname><given-names>K</given-names></name><etal/></person-group><article-title>Ketoprofen and tramadol for analgesia during early recovery after tonsillectomy in children</article-title><source>Pediatr Anesth</source><year>2006</year><volume>16</volume><fpage>548</fpage><lpage>553</lpage></element-citation></ref><ref id="b26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>WO</given-names></name><name><surname>Koo</surname><given-names>BN</given-names></name><etal/></person-group><article-title>Fentanyl-sparing effect of acetaminophen as a mixture of fentanyl in intravenous parent-/nurse-controlled analgesia after pediatric ureteroneocystostomy</article-title><source>Anesthesiology</source><year>2010</year><volume>113</volume><fpage>672</fpage><lpage>677</lpage><pub-id pub-id-type="pmid">20693884</pub-id></element-citation></ref><ref id="b27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mireskandari</surname><given-names>SM</given-names></name><name><surname>Makarem</surname><given-names>J</given-names></name></person-group><article-title>Effect of rectal diclofenac and acetaminophen alone and in combination on postoperative pain after cleft palate repair in children</article-title><source>J Craniofac Surg</source><year>2011</year><volume>22</volume><fpage>1955</fpage><lpage>1959</lpage><pub-id pub-id-type="pmid">21959480</pub-id></element-citation></ref><ref id="b28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kokki</surname><given-names>H</given-names></name><name><surname>Salonen</surname><given-names>A</given-names></name></person-group><article-title>Comparison of pre- and postoperative administration of ketoprofen for analgesia after tonsillectomy in children</article-title><source>Paediatr Anaesth</source><year>2002</year><volume>12</volume><fpage>162</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">11882229</pub-id></element-citation></ref><ref id="b29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maunuksela</surname><given-names>EL</given-names></name><name><surname>Ryhanen</surname><given-names>P</given-names></name><name><surname>Janhunen</surname><given-names>L</given-names></name></person-group><article-title>Efficacy of rectal ibuprofen in controlling postoperative pain in children</article-title><source>Can J Anaesth</source><year>1992</year><volume>39</volume><fpage>226</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">1551152</pub-id></element-citation></ref><ref id="b30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maunuksela</surname><given-names>EL</given-names></name><name><surname>Olkkola</surname><given-names>KT</given-names></name><name><surname>Korpela</surname><given-names>R</given-names></name></person-group><article-title>Does prophylactic intravenous infusion of indomethacin improve the management of postoperative pain in children?</article-title><source>Can J Anaesth</source><year>1988</year><volume>35</volume><fpage>123</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">3281764</pub-id></element-citation></ref><ref id="b31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>JY</given-names></name><name><surname>Won Han</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>WO</given-names></name><etal/></person-group><article-title>Fentanyl sparing effects of combined ketorolac and acetaminophen for outpatient inguinal hernia repair in children</article-title><source>J Urol</source><year>2010</year><volume>183</volume><fpage>1551</fpage><lpage>1555</lpage><pub-id pub-id-type="pmid">20172547</pub-id></element-citation></ref><ref id="b32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dashti</surname><given-names>GA</given-names></name><name><surname>Amini</surname><given-names>S</given-names></name><name><surname>Zanguee</surname><given-names>E</given-names></name></person-group><article-title>The prophylactic effect of rectal acetaminophen on postoperative pain and opioid requirements after adenotonsillectomy in children</article-title><source>Middle East J Anesthesiol</source><year>2009</year><volume>20</volume><fpage>245</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">19583073</pub-id></element-citation></ref><ref id="b33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korpela</surname><given-names>R</given-names></name><name><surname>Silvola</surname><given-names>J</given-names></name><name><surname>Laakso</surname><given-names>E</given-names></name><etal/></person-group><article-title>Oral naproxen but not oral paracetamol reduces the need for rescue analgesic after adenoidectomy in children</article-title><source>Acta Anaesthesiol Scand</source><year>2007</year><volume>51</volume><fpage>726</fpage><lpage>730</lpage><pub-id pub-id-type="pmid">17465970</pub-id></element-citation></ref><ref id="b34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheeran</surname><given-names>PW</given-names></name><name><surname>Rose</surname><given-names>JB</given-names></name><name><surname>Fazi</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Rofecoxib administration to paediatric patients undergoing adenotonsillectomy</article-title><source>Pediatr Anesth</source><year>2004</year><volume>14</volume><fpage>579</fpage><lpage>583</lpage></element-citation></ref><ref id="b35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viitanen</surname><given-names>H</given-names></name><name><surname>Tuominen</surname><given-names>N</given-names></name><name><surname>Vaaraniemi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Analgesic efficacy of rectal acetaminophen and ibuprofen alone or in combination for paediatric day-case adenoidectomy</article-title><source>Br J Anaesth</source><year>2003</year><volume>91</volume><fpage>363</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">12925475</pub-id></element-citation></ref><ref id="b36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuomilehto</surname><given-names>H</given-names></name><name><surname>Kokki</surname><given-names>H</given-names></name></person-group><article-title>Parenteral ketoprofen for pain management after adenoidectomy: comparison of intravenous and intramuscular routes of administration</article-title><source>Acta Anaesthesiol Scand</source><year>2002</year><volume>46</volume><fpage>184</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">11942868</pub-id></element-citation></ref><ref id="b37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bremerich</surname><given-names>DH</given-names></name><name><surname>Neidhart</surname><given-names>G</given-names></name><name><surname>Heimann</surname><given-names>K</given-names></name><etal/></person-group><article-title>Prophylactically-administered rectal acetaminophen does not reduce postoperative opioid requirements in infants and small children undergoing elective cleft palate repair</article-title><source>Anesth Analg</source><year>2001</year><volume>92</volume><fpage>907</fpage><lpage>912</lpage><pub-id pub-id-type="pmid">11273923</pub-id></element-citation></ref><ref id="b38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kokki</surname><given-names>H</given-names></name><name><surname>Tuomilehto</surname><given-names>H</given-names></name><name><surname>Tuovinen</surname><given-names>K</given-names></name></person-group><article-title>Pain management after adenoidectomy with ketoprofen: comparison of rectal and intravenous routes</article-title><source>Br J Anaesth</source><year>2000</year><volume>85</volume><fpage>836</fpage><lpage>840</lpage><pub-id pub-id-type="pmid">11732515</pub-id></element-citation></ref><ref id="b39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korpela</surname><given-names>R</given-names></name><name><surname>Korvenoja</surname><given-names>P</given-names></name><name><surname>Meretoja</surname><given-names>OA</given-names></name></person-group><article-title>Morphine-sparing effect of acetaminophen in pediatric day-case surgery</article-title><source>Anesthesiology</source><year>1999</year><volume>91</volume><fpage>442</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">10443608</pub-id></element-citation></ref><ref id="b40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kokki</surname><given-names>H</given-names></name><name><surname>Homan</surname><given-names>E</given-names></name><name><surname>Tuovinen</surname><given-names>K</given-names></name><etal/></person-group><article-title>Preoperative treatment with i.v. ketoprofen reduces pain and vomiting in children after strabismus surgery</article-title><source>Acta Anaesthesiol Scand</source><year>1999</year><volume>43</volume><fpage>13</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">9926181</pub-id></element-citation></ref><ref id="b41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kokki</surname><given-names>H</given-names></name><name><surname>Nikanne</surname><given-names>E</given-names></name><name><surname>Tuovinen</surname><given-names>K</given-names></name></person-group><article-title>I.v. intraoperative ketoprofen in small children during adenoidectomy: a dose-finding study</article-title><source>Br J Anaesth</source><year>1998</year><volume>81</volume><fpage>870</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">10211011</pub-id></element-citation></ref><ref id="b42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romsing</surname><given-names>J</given-names></name><name><surname>Ostergaard</surname><given-names>D</given-names></name><name><surname>Walther-Larsen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Analgesic efficacy and safety of preoperative vs postoperative ketorolac in paediatric tonsillectomy</article-title><source>Acta Anaesthesiol Scand</source><year>1998</year><volume>42</volume><fpage>770</fpage><lpage>775</lpage><pub-id pub-id-type="pmid">9698951</pub-id></element-citation></ref><ref id="b43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikanne</surname><given-names>E</given-names></name><name><surname>Kokki</surname><given-names>H</given-names></name><name><surname>Tuovinen</surname><given-names>K</given-names></name></person-group><article-title>IV perioperative ketoprofen in small children during adenoidectomy</article-title><source>Br J Anaesth</source><year>1997</year><volume>78</volume><fpage>24</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">9059199</pub-id></element-citation></ref><ref id="b44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bean-Lijewski</surname><given-names>JD</given-names></name><name><surname>Hunt</surname><given-names>RD</given-names></name></person-group><article-title>Effect of ketorolac on bleeding time and postoperative pain in children: a double-blind, placebo-controlled comparison with meperidine</article-title><source>J Clin Anesth</source><year>1996</year><volume>8</volume><fpage>25</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">8695075</pub-id></element-citation></ref><ref id="b45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutters</surname><given-names>KA</given-names></name><name><surname>Levine</surname><given-names>JD</given-names></name><name><surname>Dibble</surname><given-names>S</given-names></name><etal/></person-group><article-title>Analgesic efficacy and safety of single-dose intramuscular ketorolac for postoperative pain management in children following tonsillectomy</article-title><source>Pain</source><year>1995</year><volume>61</volume><fpage>145</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">7644238</pub-id></element-citation></ref><ref id="b46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watcha</surname><given-names>MF</given-names></name><name><surname>Jones</surname><given-names>MB</given-names></name><name><surname>Lagueruela</surname><given-names>RG</given-names></name><etal/></person-group><article-title>Comparison of ketorolac and morphine as adjuvants during pediatric surgery</article-title><source>Anesthesiology</source><year>1992</year><volume>76</volume><fpage>368</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">1539847</pub-id></element-citation></ref><ref id="b47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuomilehto</surname><given-names>H</given-names></name><name><surname>Kokki</surname><given-names>H</given-names></name><name><surname>Tuovinen</surname><given-names>K</given-names></name></person-group><article-title>Comparison of intravenous and oral ketoprofen for postoperative pain after adenoidectomy in children</article-title><source>Br J Anaesth</source><year>2000</year><volume>85</volume><fpage>224</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">10992828</pub-id></element-citation></ref><ref id="b48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elia</surname><given-names>N</given-names></name><name><surname>Lysakowski</surname><given-names>C</given-names></name><name><surname>Tramer</surname><given-names>MR</given-names></name></person-group><article-title>Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Meta-analyses of randomized trials</article-title><source>Anesthesiology</source><year>2005</year><volume>103</volume><fpage>1296</fpage><lpage>1304</lpage><pub-id pub-id-type="pmid">16306743</pub-id></element-citation></ref><ref id="b49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansermino</surname><given-names>M</given-names></name><name><surname>Basu</surname><given-names>R</given-names></name><name><surname>Vandebeek</surname><given-names>C</given-names></name><etal/></person-group><article-title>Nonopioid additives to local anaesthetics for caudal blockade in children: a systematic review</article-title><source>Paediatr Anaesth</source><year>2003</year><volume>13</volume><fpage>561</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">12950855</pub-id></element-citation></ref><ref id="b50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Power</surname><given-names>NM</given-names></name><name><surname>Howard</surname><given-names>RF</given-names></name><name><surname>Wade</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Pain and behaviour changes in children following surgery</article-title><source>Arch Dis Child</source><year>2012</year><volume>97</volume><fpage>879</fpage><lpage>884</lpage><pub-id pub-id-type="pmid">22806233</pub-id></element-citation></ref><ref id="b51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>DW</given-names></name><name><surname>Ragg</surname><given-names>PG</given-names></name><name><surname>Sheppard</surname><given-names>S</given-names></name><etal/></person-group><article-title>The severity and duration of postoperative pain and analgesia requirements in children after tonsillectomy, orchidopexy, or inguinal hernia repair</article-title><source>Pediatr Anesth</source><year>2012</year><volume>22</volume><fpage>136</fpage><lpage>143</lpage></element-citation></ref><ref id="b52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGrath</surname><given-names>PJ</given-names></name><name><surname>Walco</surname><given-names>GA</given-names></name><name><surname>Turk</surname><given-names>DC</given-names></name><etal/></person-group><article-title>Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations</article-title><source>J Pain</source><year>2008</year><volume>9</volume><fpage>771</fpage><lpage>783</lpage><pub-id pub-id-type="pmid">18562251</pub-id></element-citation></ref><ref id="b53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berde</surname><given-names>CB</given-names></name><name><surname>Walco</surname><given-names>GA</given-names></name><name><surname>Krane</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Pediatric analgesic clinical trial designs, measures, and extrapolation: report of an FDA scientific workshop</article-title><source>Pediatrics</source><year>2012</year><volume>129</volume><fpage>354</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">22250028</pub-id></element-citation></ref><ref id="b54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovac</surname><given-names>AL</given-names></name></person-group><article-title>Management of postoperative nausea and vomiting in children</article-title><source>Paediatr Drugs</source><year>2007</year><volume>9</volume><fpage>47</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">17291136</pub-id></element-citation></ref><ref id="b55"><label>55</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>AS</given-names></name><name><surname>Brennan</surname><given-names>L</given-names></name><name><surname>Courtman</surname><given-names>S</given-names></name><etal/></person-group><article-title>Guidelines on the Prevention of Post-operative Vomiting in Children</article-title><year>2009</year><publisher-loc>Great Britain and Ireland</publisher-loc><publisher-name>The Association of Paediatric Anaesthetists</publisher-name></element-citation></ref><ref id="b56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Standing</surname><given-names>JF</given-names></name><name><surname>Ooi</surname><given-names>K</given-names></name><name><surname>Keady</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prospective observational study of adverse drug reactions to diclofenac in children</article-title><source>Br J Clin Pharmacol</source><year>2009</year><volume>68</volume><fpage>243</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">19694745</pub-id></element-citation></ref><ref id="b57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardwell</surname><given-names>M</given-names></name><name><surname>Siviter</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name></person-group><article-title>Non-steroidal anti-inflammatory drugs and perioperative bleeding in paediatric tonsillectomy</article-title><source>Cochrane Database Syst Rev</source><year>2005</year><volume>18</volume><fpage>CD003591</fpage><pub-id pub-id-type="pmid">15846670</pub-id></element-citation></ref><ref id="b58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>BJ</given-names></name><name><surname>van Lingen</surname><given-names>RA</given-names></name><name><surname>Hansen</surname><given-names>TG</given-names></name><etal/></person-group><article-title>Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis</article-title><source>Anesthesiology</source><year>2002</year><volume>96</volume><fpage>1336</fpage><lpage>1345</lpage><pub-id pub-id-type="pmid">12170045</pub-id></element-citation></ref><ref id="b59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>BJ</given-names></name><name><surname>Woolard</surname><given-names>GA</given-names></name><name><surname>Holford</surname><given-names>NH</given-names></name></person-group><article-title>Pharmacokinetics of rectal paracetamol after major surgery in children</article-title><source>Paediatr Anaesth</source><year>1995</year><volume>5</volume><fpage>237</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">7489454</pub-id></element-citation></ref><ref id="b60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>BJ</given-names></name><name><surname>Woollard</surname><given-names>GA</given-names></name><name><surname>Holford</surname><given-names>NH</given-names></name></person-group><article-title>Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy</article-title><source>Eur J Clin Pharmacol</source><year>2001</year><volume>57</volume><fpage>559</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">11758634</pub-id></element-citation></ref><ref id="b61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceelie</surname><given-names>I</given-names></name><name><surname>de Wildt</surname><given-names>SN</given-names></name><name><surname>van Dijk</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effect of intravenous paracetamol on postoperative morphine requirements in neonates and infants undergoing major noncardiac surgery: a randomized controlled trial</article-title><source>JAMA</source><year>2013</year><volume>309</volume><fpage>149</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">23299606</pub-id></element-citation></ref><ref id="b62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allegaert</surname><given-names>K</given-names></name><name><surname>Palmer</surname><given-names>GM</given-names></name><name><surname>Anderson</surname><given-names>BJ</given-names></name></person-group><article-title>The pharmacokinetics of intravenous paracetamol in neonates: size matters most</article-title><source>Arch Dis Child</source><year>2011</year><volume>96</volume><fpage>575</fpage><lpage>580</lpage><pub-id pub-id-type="pmid">21317433</pub-id></element-citation></ref><ref id="b63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prins</surname><given-names>SA</given-names></name><name><surname>Van Dijk</surname><given-names>M</given-names></name><name><surname>Van Leeuwen</surname><given-names>P</given-names></name><etal/></person-group><article-title>Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery</article-title><source>Pediatr Anesth</source><year>2008</year><volume>18</volume><fpage>582</fpage><lpage>592</lpage></element-citation></ref><ref id="b64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannam</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>BJ</given-names></name></person-group><article-title>Explaining the acetaminophen-ibuprofen analgesic interaction using a response surface model</article-title><source>Pediatr Anesth</source><year>2011</year><volume>21</volume><fpage>1234</fpage><lpage>1240</lpage></element-citation></ref><ref id="b65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>RA</given-names></name><name><surname>Derry</surname><given-names>CJ</given-names></name><name><surname>Derry</surname><given-names>S</given-names></name><etal/></person-group><article-title>A conservative method of testing whether combination analgesics produce additive or synergistic effects using evidence from acute pain and migraine</article-title><source>Eur J Pain</source><year>2012</year><volume>16</volume><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">22396086</pub-id></element-citation></ref></ref-list></back></article>